Science.gov

Sample records for sokal vasili roudenok

  1. A Rhetorical Perspective on the Sokal Hoax: Genre, Style, and Context

    ERIC Educational Resources Information Center

    Secor, Marie; Walsh, Lynda

    2004-01-01

    In 1996, New York University professor of physics Alan Sokal wrote a parody of an academic article he titled "Transgressing the Boundaries: Toward a Transformative Hermeneutics of Quantum Gravity." This parody escaped detection by the editors and was published in the journal "Social Text." Sokal outed his own hoax in the academic magazine "Lingua…

  2. 78 FR 51803 - Culturally Significant Objects Imported for Exhibition Determinations: “Vasily Kandinsky: From...

    Federal Register 2010, 2011, 2012, 2013, 2014

    2013-08-21

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF STATE Culturally Significant Objects Imported for Exhibition Determinations: ``Vasily Kandinsky: From Blaue Reiter... April 15, 2003), I hereby determine that the objects to be included in the exhibition ``Vasily...

  3. Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy

    PubMed Central

    Xia, Leiming; Qian, Wei; Yang, Mingzhen; Li, Qingsheng; Liu, Fei; Xie, Yanyan

    2015-01-01

    Background Tyrosine kinase inhibitors are increasingly used to treat chronic myeloid leukemia (CML), but loss of complete cytogenetic response (CCyR) indicates treatment failure. Aim To compare the efficacy of Sokal, European Treatment Outcome Study (EUTOS), and Hasford prognostic scores with 3-month and 12-month CCyR, event-free survival (EFS) and progression-free survival (PFS) in patients with chronic-phase CML (CP-CML) undergoing imatinib therapy. Methods We retrospectively analyzed the outcome of 210 patients with CP-CML treated at the First Affiliated Hospital of Anhui Medical University treated between January 2006 and December 2013. Sokal, EUTOS, and Hasford scores were compared with 3-month and 12-month CCyR, EFS, and PFS. Results Kaplan–Meier analyses revealed that 3-month and 12-month CCyR and PFS were lower in patients with high EUTOS scores, and intermediate or high Sokal and Hasford scores (all P<0.05). Furthermore, EFS was lower in patients with intermediate or high Sokal and Hasford scores (both P<0.05). Hasford score (hazard ratio =2.608, 95% confidence interval: 1.473–4.617, P=0.001) was independently associated with 3-month CCyR. Conclusion Although all three scoring systems were associated with EFS, PFS, and 3-month and 12-month CCyR in the Kaplan–Meier analyses (except EFS with EUTOS), only the Hasford score was independently associated with 3m-CCyR, while EUTOS score and Sokal score were not independently associated with any of these outcomes. PMID:26392775

  4. Development of Reflection through Learning Activity

    ERIC Educational Resources Information Center

    Zuckerman, Galina

    2004-01-01

    What kind of developmental potential is present in elementary schoolchildren but hindered by the traditional type of education? Half a century ago Daniel El'konin and Vasili Davydov, the leaders of Russian Vygotskian educational psychology started answering this question. They suggested that reflection is a basic human ability and it can be…

  5. Soils regulate and mitigate climate change

    Technology Transfer Automated Retrieval System (TEKTRAN)

    Background/Question/Methods: The interaction of soil science and ecology can be traced back to the origins of soil science as an independent discipline within the natural sciences. Vasili Dokuchaev, the founder of modern soil science, identified five soil forming factors: parent material, climate, o...

  6. Postmodernism, politics and religion

    NASA Astrophysics Data System (ADS)

    Anderson, Philip

    2008-08-01

    Alan Sokal really likes footnotes, which may have made him uniquely qualified as a hoaxer of "science studies". The original hoax, a purposely and wonderfully nonsensical paper about the epistemology of quantum gravity, appeared in 1996 in the cultural-studies journal Social Text, with the enthusiastic endorsement of its editorship of eminent postmodernists. There were 107 footnotes.

  7. Fitness and Health. Beginnings Workshop.

    ERIC Educational Resources Information Center

    Child Care Information Exchange, 2000

    2000-01-01

    Presents five articles on children's fitness and health: "Relaxation: Every Child's Right to Simply Be" (Patrice Thomas and Wendy Shepherd); "Infant Massage" (Carolyn Oleson); "Fitness and the Young Child" (James M. Poole); "Partners in Health: Helping Families Advocate for Their Children's Health Care" (Karen Sokal-Gutierrez); and "Preventing…

  8. [Intellectual hoaxes. Various observations on epistemology and the human sciences].

    PubMed

    Bricmont, J

    1999-01-01

    In 1996, a New York physicist, Alan Sokal, published an article entitled "Transgressing the boundaries: towards transformative hermeneutics of quantum gravity" in the journal of cultural studies Social Text. He later revealed that it was a hoax; In this paper, I discuss the two main issues raised by the hoax: firstly, the abuse of scientific terminology by famous intellectuals such as Lacan, Kristeva or Irigaray, and other "postmodernist" thinkers; secondly, the epistemic relativism and its impact on the history and sociology of science.

  9. The Mishin Diaries, a new significant primary source of space history information

    NASA Astrophysics Data System (ADS)

    Payson, Dmitry; Alifanov, Oleg; Moiseev, Ivan; Vick, Charles; Woods, David

    2016-06-01

    Vasily Mishin (1917-2001) was a prominent Russian engineer and scientist: one of the pioneers who made spaceflight a reality. In 2014 diaries that were maintained by Mishin from 1960 to 1974 (the Mishin Diaries) had been transcribed and published and can now serve as an extensive resource for first-hand historical information about that fascinating period of time. The original Diaries are now owned by the Perot Foundation and copies were generously provided by them to the Moscow Aviation Institute for this transcription project. The actual publication was made possible by Mishin's students, co-workers, family members as well as numerous spaceflight historians and enthusiasts.

  10. An Underdiscussed Aspect of Chomsky (1959)

    PubMed Central

    Adelman, Barry Eshkol

    2007-01-01

    Chomsky's (1959) review of Skinner's (1957) Verbal Behavior has been influential and attributed with a role in the cognitive revolution. However, while counter reviews from within behavior analysis have noted that Chomsky misunderstood the subject matter, certain aspects of his scholarship have been underdiscussed. This includes several instances where Chomsky misquotes Skinner or takes his quotes out of context. Similar to the findings of Sokal (1996a, 1996b), it is speculated that the problems with Chomsky were overlooked by cognitive psychologists because his general outlook was accepted. Implications for the editorial review process are discussed. PMID:22477378

  11. An underdiscussed aspect of chomsky (1959).

    PubMed

    Adelman, Barry Eshkol

    2007-01-01

    Chomsky's (1959) review of Skinner's (1957)Verbal Behavior has been influential and attributed with a role in the cognitive revolution. However, while counter reviews from within behavior analysis have noted that Chomsky misunderstood the subject matter, certain aspects of his scholarship have been underdiscussed. This includes several instances where Chomsky misquotes Skinner or takes his quotes out of context. Similar to the findings of Sokal (1996a, 1996b), it is speculated that the problems with Chomsky were overlooked by cognitive psychologists because his general outlook was accepted. Implications for the editorial review process are discussed.

  12. 110th Anniversary of the Engelhardt Astronomical Observatory

    NASA Astrophysics Data System (ADS)

    Nefedyev, Y.

    2012-09-01

    The Engelhardt Astronomical Observatory (EAO) was founded in September 21, 1901. The history of creation of the Engelhard Astronomical Observatory was begun in 1897 with transfer a complimentary to the Kazan University of the unique astronomical equipment of the private observatory in Dresden by known astronomer Vasily Pavlovichem Engelgardt. Having stopped astronomical activity owing to advanced years and illnesses Engelgardt has decided to offer all tools and library of the Astronomical observatory of the Kazan University. Vasily Pavlovich has put the first condition of the donation that his tools have been established as soon as possible and on them supervision are started. In 1898 the decree of Emperor had been allocated means and the ground for construction of the Astronomical observatory is allocated. There is the main historical telescope of the Engelhard Astronomical Observatory the 12-inch refractor which was constructed by English master Grubbom in 1875. The unique tool of the Engelhard Astronomical Observatory is unique in the world now a working telescope heliometer. It's one of the first heliometers, left workshops Repsolda. It has been made in 1874 and established in Engelgardt observatory in 1908 in especially for him the constructed round pavilion in diameter of 3.6 m. Today the Engelhard Astronomical Observatory is the only thing scientifically - educational and cultural - the cognitive astronomical center, located on territory from Moscow up to the most east border of Russia. Currently, the observatory is preparing to enter the protected UNESCO World Heritage List.

  13. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

    PubMed

    Hoffmann, V S; Baccarani, M; Hasford, J; Lindoerfer, D; Burgstaller, S; Sertic, D; Costeas, P; Mayer, J; Indrak, K; Everaus, H; Koskenvesa, P; Guilhot, J; Schubert-Fritschle, G; Castagnetti, F; Di Raimondo, F; Lejniece, S; Griskevicius, L; Thielen, N; Sacha, T; Hellmann, A; Turkina, A G; Zaritskey, A; Bogdanovic, A; Sninska, Z; Zupan, I; Steegmann, J-L; Simonsson, B; Clark, R E; Covelli, A; Guidi, G; Hehlmann, R

    2015-06-01

    This population-based registry was designed to provide robust and updated information on the characteristics and the epidemiology of chronic myeloid leukemia (CML). All cases of newly diagnosed Philadelphia positive, BCR-ABL1+ CML that occurred in a sample of 92.5 million adults living in 20 European countries, were registered over a median period of 39 months. 94.3% of the 2904 CML patients were diagnosed in chronic phase (CP). Median age was 56 years. 55.5% of patients had comorbidities, mainly cardiovascular (41.9%). High-risk patients were 24.7% by Sokal, 10.8% by EURO, and 11.8% by EUTOS risk scores. The raw incidence increased with age from 0.39/100,000/year in people 20-29 years old to 1.52 in those >70 years old, and showed a maximum of 1.39 in Italy and a minimum of 0.69 in Poland (all countries together: 0.99). The proportion of Sokal and Euro score high-risk patients seen in many countries indicates that trial patients were not a positive selection. Thus from a clinical point of view the results of most trials can be generalized to most countries. The incidences observed among European countries did not differ substantially. The estimated number of new CML cases per year in Europe is about 6370. PMID:25783795

  14. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients

    PubMed Central

    Yamamoto, Eri; Fujisawa, Shin; Hagihara, Maki; Tanaka, Masatsugu; Fujimaki, Katsumichi; Kishimoto, Kumiko; Hashimoto, Chizuko; Itabashi, Megumi; Ishibashi, Daisuke; Nakajima, Yuki; Tachibana, Takayoshi; Kawasaki, Rika; Kuwabara, Hideyuki; Koharazawa, Hideyuki; Yamazaki, Etsuko; Tomita, Naoto; Sakai, Rika; Fujita, Hiroyuki; Kanamori, Heiwa; Ishigatsubo, Yoshiaki

    2014-01-01

    The Sokal and Hasford scores were developed in the chemotherapy and interferon era and are widely used as prognostic indicators in patients with chronic myeloid leukemia (CML). Recently, a new European Treatment and Outcome Study (EUTOS) scoring system was developed. We performed a multicenter retrospective study to validate the effectiveness of each of the three scoring systems. The study cohort included 145 patients diagnosed with CML in chronic phase who were treated with imatinib. In the EUTOS low- and high-risk groups, the cumulative incidence of complete cytogenetic response (CCyR) at 18 months was 86.9% and 87.5% (P = 0.797) and the 5-year overall survival rate was 92.6% and 93.3% (P = 0.871), respectively. The cumulative incidence of CCyR at 12 months, 5-year event-free survival and 5-year progression-free survival were not predicted using the EUTOS scoring system. However, there were significant differences in both the Sokal score and Hasford score risk groups. In our retrospective validation study, the EUTOS score did not predict the prognosis of patients with CML in chronic phase treated with imatinib. PMID:24450386

  15. Will molecular biology contribute to refine prognosis and to select treatment? The Molecular Biology Committee. Italian Cooperative Study Group on Chronic Myeloid Leukemia.

    PubMed

    Zaccaria, A; Martinelli, G; Buzzi, M; Farabegoli, P

    1993-01-01

    The possible prognostic value of the position of the breakpoint within the M-BCR in patients with Ph1+ CML is still being debated. We analyzed the DNA rearrangements and the transcript types of 244 patients and tried to correlate the data obtained with prognostic features, defined according to Sokal's risk index, and with chronic phase and/or survival duration. The exact location of the breakpoint, either 5' or 3' to the Hind III restriction site within the M-BCR was identified. Moreover, the exact M-BCR subregion was also identified. As a whole, 150 pts were rearranged in the 5' part and 94 in the 3' part of the M-BCR. No correlation was observed between the site of rearrangement on the one hand and the Sokal's prognostic index and survival, on the other. Transcript analysis was performed in 130 patients; 59 carried an a2b2 and 69 an a2b3 pattern. Two patients carried both transcripts. Of the patients rearranged in the 5' area, according to Southern blotting, 29.2% showed an a2b3 transcript. Therefore, RT-PCR analysis allowed a better definition of the breakpoint. However, also the type of transcript did not show any correlation either with risk categories or survival. No difference in response to therapy, either chemotherapy or alpha interferon, was observed between 5' and 3' rearranged patients.

  16. The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience

    PubMed Central

    Jaźwiec, Bożena; Haus, Olga; Urbaniak-Kujda, Donata; Kapelko-Słowik, Katarzyna; Wróbel, Tomasz; Lonc, Tomasz; Sawicki, Mateusz; Mędraś, Ewa; Kaczmar-Dybko, Agnieszka; Kuliczkowski, Kazimierz

    2016-01-01

    The Sokal, Hasford, and EUTOS scores were established in different treatment eras of chronic myeloid leukemia (CML). None of them was reported to predict molecular response. In this single center study we tried to reevaluate the usefulness of three main scores in TKI era. The study group included 88 CML patients in first chronic phase treated initially with standard imatinib dose. All of them achieved major molecular response (MMR) in time points defined by European LeukemiaNet (ELN). 42 patients lost MMR in a median time of 47 months and we found a significant difference in MMR maintenance between intermediate-risk (IR) and low-risk (LR) patients assessed by Hasford score. All 42 patients were switched to second-generation TKI (2G-TKI) treatment. At 18 months of 2G-TKI therapy we have still found a significant difference in BCR-ABL transcript levels and MMR rate between IR and LR groups. We did not find any of the described differences discriminating patients by Sokal or EUTOS score. In this retrospective single center analysis we found Hasford score to be useful in predicting molecular response in first chronic phase of CML patients.

  17. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

    PubMed

    Hochhaus, Andreas; Saglio, Giuseppe; Larson, Richard A; Kim, Dong-Wook; Etienne, Gabriel; Rosti, Gianantonio; De Souza, Carmino; Kurokawa, Mineo; Kalaycio, Matt E; Hoenekopp, Albert; Fan, Xiaolin; Shou, Yaping; Kantarjian, Hagop M; Hughes, Timothy P

    2013-05-01

    In patients with chronic myeloid leukemia, BCR-ABL mutations contribute to resistance to tyrosine kinase inhibitor therapy. We examined the occurrence of treatment-emergent mutations and their impact on response in patients from the ENESTnd phase 3 trial. At the 3-year data cutoff, mutations were detected in approximately twice as many patients (21) on imatinib 400 mg once daily as on nilotinib (11 patients each on nilotinib 300 mg twice daily and nilotinib 400 mg twice daily). The majority of mutations occurred in patients with intermediate or high Sokal scores. Most mutations (14 [66.7%]) emerging during imatinib treatment were imatinib-resistant and nilotinib-sensitive. Incidence of the T315I mutation was low (found in 3, 2, and 3 patients on nilotinib 300 mg twice daily, nilotinib 400 mg twice daily, and imatinib, respectively) and mostly occurred in patients with high Sokal scores. Of the patients with emergent mutations, 1 of 11, 2 of 11, and 7 of 21 patients on nilotinib 300 mg twice daily, nilotinib 400 mg twice daily, and imatinib, respectively, progressed to accelerated phase/blast crisis (AP/BC) on treatment. Overall, nilotinib led to fewer treatment-emergent BCR-ABL mutations than imatinib and reduced rates of progression to AP/BC in patients with these mutations. (Clinicaltrials.gov NCT00471497).

  18. Archeointensities in Greece during the Neolithic period: New insights into material selection and secular variation curve

    NASA Astrophysics Data System (ADS)

    Fanjat, G.; Aidona, E.; Kondopoulou, D.; Camps, P.; Rathossi, C.; Poidras, T.

    2013-02-01

    Numerous archeomagnetic studies have provided high quality data for both the direction and the intensity of the geomagnetic field, essentially in Europe for the last 10 millennia. In particular, Greece supplies a lot of archeological materials due to its impressive cultural heritage and volcanic activity, so that numerous data have been obtained from burnt clays or historical lava flows. The most recent Greek secular variation curves are available for the last 8 millennia for the intensity and the last 6 millennia for the direction. Nevertheless, the coverage still presents several gaps for periods older than 2500 BC. In an effort to complete the Greek curve and extend it to older times, we present the archeointensity results from three Neolithic settlements in Northern Greece. The samples are of two different natures: burnt structures from Avgi (5250 ± 150 BC) and Vasili (4800 ± 200 BC), as well as ceramics from Dikili Tash (4830 ± 80 BC) and Vasili (4750 ± 250 BC). The samples have been subjected to standard rock magnetic analyses in order to estimate the thermal stability and the domain state of the magnetic carriers before archeointensity measurements. Surprisingly, very few ceramic samples provided reliable archeointensities whereas samples from burnt structures presented a very good success rate. Complementary studies showed that a detailed examination of the matrix color, following archeological information and classification standards can be a decisive test for pre-selection of sherds. In spite of these unsuccessful measurements from ceramics, we obtained an intensity value of 73.5 ± 1.1 μT for Dikili Tash, a higher value than the other data obtained in the same area, during the same period. However we do not have evidences for a technical artefact during the experiment. The burnt structures yielded two reliable archeointensities of 36.1 ± 1.8 μT and 46.6 ± 3.4 μT for Avgi and Vasili, respectively. Finally, we achieved a new archeomagnetic dating

  19. Final Scientific EFNUDAT Workshop

    ScienceCinema

    None

    2016-07-12

    The Final Scientific EFNUDAT Workshop - organized by the CERN/EN-STI group on behalf of n_TOF Collaboration - will be held at CERN, Geneva (Switzerland) from 30 August to 2 September 2010 inclusive.EFNUDAT website: http://www.efnudat.euTopics of interest include: Data evaluationCross section measurementsExperimental techniquesUncertainties and covariancesFission propertiesCurrent and future facilities  International Advisory Committee: C. Barreau (CENBG, France)T. Belgya (IKI KFKI, Hungary)E. Gonzalez (CIEMAT, Spain)F. Gunsing (CEA, France)F.-J. Hambsch (IRMM, Belgium)A. Junghans (FZD, Germany)R. Nolte (PTB, Germany)S. Pomp (TSL UU, Sweden) Workshop Organizing Committee: Enrico Chiaveri (Chairman)Marco CalvianiSamuel AndriamonjeEric BerthoumieuxCarlos GuerreroRoberto LositoVasilis Vlachoudis Workshop Assistant: Géraldine Jean

  20. A Grand Solar Plan: How Solar Power can Cut Greenhouse Gases and End U.S. Dependence on Foreign Oil (436th Brookhaven Lecture)

    SciTech Connect

    Fthenakis, Vasilis

    2008-04-21

    With oil now around $100 per barrel, solar power is no longer impractical, notes BNL's Vasilis Fthenakis, who, with two of his collaborators, authored "A Grand Solar Plan," the cover story of the January 2008 issue of Scientific American. As Dr. Fthenakis will detail in his special, open-to-the-public Earth Day lecture co-sponsored by the Brookhaven Lecture Committee and the Environment & Waste Management Services Division, the three solar experts propose covering thousands of square miles of the Southwest U.S. with photovoltaic arrays. These would convert sunlight into electricity, which would then be distributed across the U.S. -- ending foreign-oil dependence, reducing the trade deficit, cutting air pollution, and slowing global climate change. Given oil's record price, the time for solar power as an affordable and technically implementable solution is now -- if, according to Dr. Fthenakis, the U.S. makes the commitment and investment.

  1. Final Scientific EFNUDAT Workshop

    SciTech Connect

    2010-11-09

    The Final Scientific EFNUDAT Workshop - organized by the CERN/EN-STI group on behalf of n_TOF Collaboration - will be held at CERN, Geneva (Switzerland) from 30 August to 2 September 2010 inclusive.EFNUDAT website: http://www.efnudat.euTopics of interest include: Data evaluationCross section measurementsExperimental techniquesUncertainties and covariancesFission propertiesCurrent and future facilities  International Advisory Committee: C. Barreau (CENBG, France)T. Belgya (IKI KFKI, Hungary)E. Gonzalez (CIEMAT, Spain)F. Gunsing (CEA, France)F.-J. Hambsch (IRMM, Belgium)A. Junghans (FZD, Germany)R. Nolte (PTB, Germany)S. Pomp (TSL UU, Sweden) Workshop Organizing Committee: Enrico Chiaveri (Chairman)Marco CalvianiSamuel AndriamonjeEric BerthoumieuxCarlos GuerreroRoberto LositoVasilis Vlachoudis Workshop Assistant: Géraldine Jean

  2. Comittees

    NASA Astrophysics Data System (ADS)

    2004-10-01

    Fritz Caspers (CERN, Switzerland), Michel Chanel (CERN, Switzerland), Håkan Danared (MSL, Sweden), Bernhard Franzke (GSI, Germany), Manfred Grieser (MPI für Kernphysik, Germany), Dieter Habs (LMU München, Germany), Jeffrey Hangst (University of Aarhus, Denmark), Takeshi Katayama (RIKEN/Univ. Tokyo, Japan), H.-Jürgen Kluge (GSI, Germany), Shyh-Yuan Lee (Indiana University, USA), Rudolf Maier (FZ Jülich, Germany), John Marriner (FNAL, USA), Igor Meshkov (JINR, Russia), Dieter Möhl (CERN, Switzerland), Vasily Parkhomchuk (BINP, Russia), Robert Pollock (Indiana University), Dieter Prasuhn (FZ Jülich, Germany), Dag Reistad (TSL, Sweden), John Schiffer (ANL, USA), Andrew Sessler (LBNL, USA), Alexander Skrinsky (BINP, Russia), Markus Steck (GSI, Germany), Jie Wei (BNL, USA), Andreas Wolf (MPI für Kernphysik, Germany), Hongwei Zhao (IMP, People's Rep. of China).

  3. Updated thinking on positivity ratios.

    PubMed

    Fredrickson, Barbara L

    2013-12-01

    This article presents my response to the article by Brown, Sokal, and Friedman (2013), which critically examined Losada's conceptual and mathematical work (as presented in Losada, 1999; Losada & Heaphy, 2004; and Fredrickson & Losada; 2005) and concluded that mathematical claims for a critical tipping point positivity ratio are unfounded. In the present article, I draw recent empirical evidence together to support the continued value of computing and seeking to elevate positivity ratios. I also underscore the necessity of modeling nonlinear effects of positivity ratios and, more generally, the value of systems science approaches within affective science and positive psychology. Even when scrubbed of Losada's now-questioned mathematical modeling, ample evidence continues to support the conclusion that, within bounds, higher positivity ratios are predictive of flourishing mental health and other beneficial outcomes. PMID:23855895

  4. Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients

    PubMed Central

    Qin, Ya-Zhen; Jiang, Qian; Jiang, Hao; Lai, Yue-Yun; Zhu, Hong-Hu; Liu, Yan-Rong; Jiang, Bin; Huang, Xiao-Jun

    2016-01-01

    Abstract The aim of this study was to evaluate the impact of white blood cell (WBC) counts at presentation on the achievement of deep molecular response. A total of 362 newly diagnosed chronic-phase chronic myeloid leukemia patients (CML-CP) receiving 400 mg/day imatinib were serially monitored for a median of 36 months (range 6–115). Patients showing an optimal response at 3, 6, and 12 months as defined by the 2013 European LeukemiaNet recommendations had significantly lower WBC counts at presentation than those showing nonoptimal responses (all P < 0.0001). Among the cutoff values with a similar Youden index, 150 × 10E9/L (abbreviated WBC > 150) was selected to identify the greatest amount of patients with the potential to achieve a sustained molecular response of 4.5 (MR4.5). Regardless of whether the Sokal risk score was included, the BCR-ABLIS value at 3 months, WBC counts at presentation, hemoglobin levels, and sex were the common independent predictors for an MR4.5, with the former 2 presenting the highest hazard risk. Low Sokal risk scores did not independently predict the achievement of an MR4.5. Patients with concurrent WBC > 150 and BCR-ABLIS ≤ 10% had a similar incidence of 4-year MR4.5 compared with patients with concurrent WBC ≤ 150 and BCR-ABLIS > 10% and concurrent WBC > 150 and BCR-ABLIS > 10% (13.5% vs 13.2% vs 8.8%, P = 0.47), and all of these values were significantly lower than the values for patients with concurrent WBC ≤ 150 and BCR-ABLIS ≤ 10% (55.0%, all P < 0.0001). Patients with concurrent WBC ≤ 150 and BCR-ABLIS ≤ 10% had better 4-year event-free survival rates, progression-free survival rates, and overall survival rates compared with patients with WBC > 150 or BCR-ABLIS > 10%. The combination of WBC count at presentation and BCR-ABLIS at 3 months provides improved predictions of deep molecular response in imatinib-treated CML-CP patients. Therefore, the WBC count at presentation might be used to

  5. Autologous stem cell transplantation in chronic myeloid leukemia: a single center experience.

    PubMed

    Pigneux, A; Faberes, C; Boiron, J M; Mahon, F X; Cony-Makhoul, P; Agape, P; Lounici, A; Bernard, P; Bilhou-Nabera, C; Bouzgarrou, R; Marit, G; Reiffers, J

    1999-08-01

    Between 1980 and 1996, we transplanted 72 patients with CML using blood stem cells collected at diagnosis before treatment and without any mobilization. The median age of patients at diagnosis was 47.5 years (range 20.5-59.5). The median numbers of nucleated cells and CFU-GM transplanted were 10 x 10(8)/kg and 97 x 10(4)/kg, respectively. The median duration to reach more than 0.5 x 10(9)/l neutrophils and 50 x 10(9)/l platelets was 12 (range 5-19) and 11 days (range 0-79), respectively. Twenty patients (group I) were transplanted in chronic phase either for resistance to IFN (14 patients) (group IA) or because the Sokal index was more than 1.2 (six patients) (group IB). All those patients had preparative regimen with busulfan (4 mg/kg/day x 4) and melphalan (140 mg/m2). They were treated with recombinant alpha-interferon (IFN) after transplant. The cumulative incidence of major cytogenetic response (MCR) at 12 months was 25 +/- 21% (95% CI), the 5-year survival was 75 +/- 42% (95% CI). These results (observed in patients with bad prognosis factors) are similar to those usually observed in CML patients treated by IFN, whatever the Sokal risk. Thus autologous transplantation is able to reproduce for poor prognosis patients the results observed in standard risk patients treated with IFN. This suggests that it could prolong survival. Fifty-two other patients (group II) were transplanted for CML in transformation (accelerated phase = 32; blast crisis = 20) after a preparative regimen containing either total body irradiation (TBI) or busulfan. The median survival was short (10.4 months) and only 21 patients survived more than 1 year. The survival was longer for patients transplanted in accelerated phase (vs blast crisis), those who were due to receive a double transplant (vs single) (34 patients), those who were treated with IFN after transplant (vs hydroxyurea) and for the patients who obtained a complete hematologic response.

  6. Synaesthesia, the arts and creativity: a neurological connection.

    PubMed

    Mulvenna, Catherine M

    2007-01-01

    For over 100 years the link between synaesthesia and the arts has attracted controversy. This has been spurred by the production of auditory, literary and visual art by famous individuals who report experiences synonymous with the neurological condition. Impressive protagonists in this discussion include Arthur Rimbaud, Charles Baudelaire, Vasily Kandinsky, Vladimir Nabokov, Alexander Scriabin, Olivier Messiaen and David Hockney. Interdisciplinary debates have concerned whether synaesthesia can actively contribute to an artist's ability, whether it is a driving force or a mere idiosyncratic quirk and whether, fundamentally, it is a distinct idiopathic condition or an unusual metaphorical description of normal perception. Recent psychological and neuroscientific evidence offers a new level to the debate. Coherent patterns of a neural basis of synaesthesia have been confirmed with high spatial resolution brain imaging techniques and the link with the arts is transpiring to be more than superficial or coincidental. Moreover, the neural distinction of the synaesthete brain may prove to be a window into a neural basis of creative cognition, and therefore conducive to the expression of creativity in various media.

  7. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

    PubMed Central

    Sandin, Fredrik; Hellström, Karin; Björeman, Mats; Björkholm, Magnus; Brune, Mats; Dreimane, Arta; Ekblom, Marja; Lehmann, Sören; Ljungman, Per; Malm, Claes; Markevärn, Berit; Myhr-Eriksson, Kristina; Ohm, Lotta; Olsson-Strömberg, Ulla; Själander, Anders; Wadenvik, Hans; Simonsson, Bengt; Stenke, Leif; Richter, Johan

    2013-01-01

    Clinical management guidelines on malignant disorders are generally based on data from clinical trials with selected patient cohorts. In Sweden, more than 95% of all patients diagnosed with chronic myeloid leukemia (CML) are reported to the national CML registry, providing unique possibilities to compile population-based information. This report is based on registry data from 2002 to 2010, when a total of 779 patients (425 men, 354 women; median age, 60 years) were diagnosed with CML (93% chronic, 5% accelerated, and 2% blastic phase) corresponding to an annual incidence of 0.9/100 000. In 2002, approximately half of the patients received a tyrosine kinase inhibitor as initial therapy, a proportion that increased to 94% for younger (<70 years) and 79% for older (>80 years) patients during 2007-2009. With a median follow-up of 61 months, the relative survival at 5 years was close to 1.0 for patients younger than 60 years and 0.9 for those aged 60 to 80 years, but only 0.6 for those older than 80 years. At 12 months, 3% had progressed to accelerated or blastic phase. Sokal, but not European Treatment and Outcome Study, high-risk scores were significantly linked to inferior overall and relative survival. Patients living in university vs nonuniversity catchment areas more often received tyrosine kinase inhibitors up front but showed comparable survival. PMID:23843494

  8. Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor

    PubMed Central

    Vaidya, Shantashri; Vundinti, Babu Rao; Shanmukhaiah, Chandrakala; Chakrabarti, Prantar; Ghosh, Kanjaksha

    2015-01-01

    Background Mutations in the ABL kinase domain and SH3-SH2 domain of the BCR/ABL gene and amplification of the Philadelphia chromosome are the two important BCR/ABL dependent mechanisms of imatinib resistance. Here, we intended to study the role played by TKI, imatinib, in selection of gene mutations and development of chromosomal abnormalities in Indian CML patients. Methods Direct sequencing methodology was employed to detect mutations and conventional cytogenetics was done to identify Philadelphia duplication. Results Among the different mechanisms of imatinib resistance, kinase domain mutations (39%) of the BCR/ABL gene were seen to be more prevalent, followed by mutations in the SH3-SH2 domain (4%) and then BCR/ABL amplification with the least frequency (1%). The median duration of occurrence of mutation was significantly shorter for patients with front line imatinib than those pre-treated with hydroxyurea. Patients with high Sokal score (p = 0.003) showed significantly higher incidence of mutations, as compared to patients with low/intermediate score. Impact of mutations on the clinical outcome in AP and BC was observed to be insignificant. Of the 94 imatinib resistant patients, only 1 patient exhibited duplication of Philadelphia chromosome, suggesting a less frequent occurrence of this abnormality in Indian CML patients. Conclusion Close monitoring at regular intervals and proper analysis of the disease resistance would facilitate early detection of resistance and thus aid in the selection of the most appropriate therapy. PMID:25629972

  9. PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase.

    PubMed

    Alonso-Dominguez, Juan M; Grinfeld, Jacob; Alikian, Mary; Marin, David; Reid, Alistair; Daghistani, Mustafa; Hedgley, Corinne; O'Brien, Stephen; Clark, Richard E; Apperley, Jane; Foroni, Letizia; Gerrard, Gareth

    2015-01-01

    The tyrosine kinase inhibitor (TKI) imatinib has revolutionized the management of chronic myeloid leukaemia (CML). However, around 25% of patients fail to sustain an adequate response. We sought to identify gene-expression biomarkers that could be used to predict imatinib response. The expression of 29 genes, previously implicated in CML pathogenesis, were measured by TaqMan Low Density Array in 73 CML patient samples. Patients were divided into low and high expression for each gene and imatinib failure (IF), probability of achieving CCyR, progression free survival and CML related OS were compared by Kaplan-Meier and log-rank. Results were validated in a second cohort of 56 patients, with a further technical validation using custom gene-expression assays in a conventional RT-qPCR in a sub-cohort of 37 patients. Patients with low PTCH1 expression showed a worse clinical response for all variables in all cohorts. PTCH1 was the most significant predictor in the multivariate analysis compared with Sokal, age and EUTOS. PTCH1 expression assay showed the adequate sensitivity, specificity and predictive values to predict for IF. Given the different treatments available for CML, measuring PTCH1 expression at diagnosis may help establish who will benefit best from imatinib and who is better selected for second generation TKI. PMID:25250944

  10. Plasmid and restriction endonuclease patterns in Pasteurella multocida isolated from a swine pyramid.

    PubMed

    Rúbies, Xavier; Casal, Jordi; Pijoan, Carlos

    2002-01-01

    Restriction endonuclease analysis (REA) and plasmid profile were used to study the epidemiology of Pasteurella multocida in a swine pyramid structure. The studied pyramid was comprised of a group of 12 swine farrow-to-finish farms related by unidirectional animal movement. P. multocida isolates were obtained from the lungs of 275 slaughtered pigs. Serotyping was performed by hyaluronidase sensitivity test and toxicity was investigated by the ELISA test. HpaII was used to cleave the P. multocida extracted DNA. REA patterns relationships were studied using the Sokal-Michener coefficients, and the dendrogram was built using the UPGMA system. The 218 P. multocida isolates obtained were distributed in 17 REA patterns. In 9 of the 12 farms studied only 2-3 REA patterns were detected, with one clearly predominant pattern. The 81 strains with plasmids were assigned to six plasmid profiles. REA and plasmid profiles proved to be good epidemiological tools for identifying different strains of P. multocida with the same phenotype.

  11. Plasmid and restriction endonuclease patterns in Pasteurella multocida isolated from a swine pyramid.

    PubMed

    Rúbies, Xavier; Casal, Jordi; Pijoan, Carlos

    2002-01-01

    Restriction endonuclease analysis (REA) and plasmid profile were used to study the epidemiology of Pasteurella multocida in a swine pyramid structure. The studied pyramid was comprised of a group of 12 swine farrow-to-finish farms related by unidirectional animal movement. P. multocida isolates were obtained from the lungs of 275 slaughtered pigs. Serotyping was performed by hyaluronidase sensitivity test and toxicity was investigated by the ELISA test. HpaII was used to cleave the P. multocida extracted DNA. REA patterns relationships were studied using the Sokal-Michener coefficients, and the dendrogram was built using the UPGMA system. The 218 P. multocida isolates obtained were distributed in 17 REA patterns. In 9 of the 12 farms studied only 2-3 REA patterns were detected, with one clearly predominant pattern. The 81 strains with plasmids were assigned to six plasmid profiles. REA and plasmid profiles proved to be good epidemiological tools for identifying different strains of P. multocida with the same phenotype. PMID:11731160

  12. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

    PubMed Central

    Hochhaus, A; Saglio, G; Hughes, T P; Larson, R A; Kim, D-W; Issaragrisil, S; le Coutre, P D; Etienne, G; Dorlhiac-Llacer, P E; Clark, R E; Flinn, I W; Nakamae, H; Donohue, B; Deng, W; Dalal, D; Menssen, H D; Kantarjian, H M

    2016-01-01

    In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a lower risk of progression to accelerated phase/blast crisis (AP/BC) than imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Here, patients' long-term outcomes in ENESTnd are evaluated after a minimum follow-up of 5 years. By 5 years, more than half of all patients in each nilotinib arm (300 mg twice daily, 54% 400 mg twice daily, 52%) achieved a molecular response 4.5 (MR4.5; BCR-ABL⩽0.0032% on the International Scale) compared with 31% of patients in the imatinib arm. A benefit of nilotinib was observed across all Sokal risk groups. Overall, safety results remained consistent with those from previous reports. Numerically more cardiovascular events (CVEs) occurred in patients receiving nilotinib vs imatinib, and elevations in blood cholesterol and glucose levels were also more frequent with nilotinib. In contrast to the high mortality rate associated with CML progression, few deaths in any arm were associated with CVEs, infections or pulmonary diseases. These long-term results support the positive benefit-risk profile of frontline nilotinib 300 mg twice daily in patients with CML-CP. PMID:26837842

  13. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

    PubMed Central

    Saglio, Giuseppe; Kantarjian, Hagop M.; Guilhot, François; Niederwieser, Dietger; Rosti, Gianantonio; Nakaseko, Chiaki; De Souza, Carmino Antonio; Kalaycio, Matt E.; Meier, Stephan; Fan, Xiaolin; Menssen, Hans D.; Larson, Richard A.; Hochhaus, Andreas

    2014-01-01

    We explored the impact of early molecular response (EMR; BCR-ABL ≤10% on the international scale [BCR-ABLIS] at 3 or 6 months) on outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with nilotinib or imatinib based on 4 years of follow up in Evaluating Nilotinib Efficacy and Safety in Clinical Trials—Newly Diagnosed Patients. Patients (n = 846) received nilotinib 300 mg twice daily, nilotinib 400 mg twice daily, or imatinib 400 mg once daily. At 3 months, more patients had EMR failure (ie, BCR-ABLIS >10%) on imatinib (33%) than on nilotinib (9%-11%); similarly at 6 months, 16% of patients in the imatinib arm vs 3% and 7% in the nilotinib arms had EMR failure. In all arms, EMR failure was associated with lower rates of molecular response, an increased risk of progression, and lower overall survival compared with EMR achievement. We also analyzed patient and treatment characteristics associated with EMR and found distinct patterns in the nilotinib arms vs the imatinib arm. High Sokal risk score was associated with a high rate of EMR failure on imatinib, but not on nilotinib. In contrast, reduced dose intensity and dose interruptions were strongly associated with EMR failure in nilotinib-treated, but not imatinib-treated, patients. This study is registered at www.clinicaltrials.gov as #NCT00471497. PMID:24335106

  14. Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans.

    PubMed

    Aïssata, Tolo Diebkilé; Sawadogo, Duni; Nanho, Clotaire; Kouakou, Boidy; Meité, N'dogomo; Emeuraude, N'dhatz; Roméo, Ayémou; Yassongui Mamadou, Sekongo; Kouéhion, Paul; Mozart, Konan; Koffi, Gustave; Sanogo, Ibrahima

    2013-01-01

    Imatinib mesylate provides good results in the treatment of CML in general. But what about the results of this treatment in CML associated with additional cytogenetic abnormalities at diagnosis among black Africans? For this, we retrospectively studied 27 cases of CML associated with additional cytogenetic abnormalities, diagnosed in the department of clinical hematology of the University Hospital of Yopougon in Côte d'Ivoire, from May 2005 to October 2011. The age of patients ranged from 13 to 68 years, with a mean age of 38 years and a sex ratio of 2. Patients were severely symptomatic with a high Sokal score of 67%. CML in chronic phase accounted for 67%. The prevalence of additional cytogenetic abnormalities was 29.7%. There were variants of the Philadelphia chromosome (18.5%), trisomy 8 (14.8%), complex cytogenetic abnormalities (18.5%), second Philadelphia chromosome (14.8%), and minor cytogenetic abnormalities (44.4%). Complete hematologic remission was achieved in 59%, with 52% of major cytogenetic remission. The outcome was fatal in 37% of patients. Death was related in 40% to hematologic toxicity and in 30% to acutisation. The median survival was 40 months.

  15. Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib.

    PubMed

    Janssen, J J W M; Deenik, W; Smolders, K G M; van Kuijk, B J; Pouwels, W; Kelder, A; Cornelissen, J J; Schuurhuis, G J; Ossenkoppele, G J

    2012-05-01

    Insensitivity of chronic myeloid leukemia (CML) hematopoietic stem cells to tyrosine kinase inhibitors (TKIs) prevents eradication of the disease and may be involved in clinical resistance. For improved treatment results more knowledge about CML stem cells is needed. We here present a new flow cytometric approach enabling prospective discrimination of CML stem cells from their normal counterparts within single-patient samples. In 24 of 40 newly diagnosed CML patients residual normal CD34(+)CD38(-) stem cells could be identified by lower CD34 and CD45 expression, lower forward/sideward light scatter and by differences of lineage marker expression (CD7, CD11b and CD56) and of CD90. fluorescent in situ hybridization (FISH) analysis on Fluorescence-activated cell sorting sorted cells proved that populations were BCR-ABL positive or negative and long-term liquid culture assays with subsequent colony forming unit assays and FISH analysis proved their stem cell character. Patients with residual non-leukemic stem cells had lower clinical risk scores (Sokal, Euro), lower hematological toxicity of imatinib (IM) and better molecular responses to IM than patients without. This new approach will expand our possibilities to separate CML and normal stem cells, present in a single bone marrow or peripheral blood sample, thereby offering opportunities to better identify new CML stem-cell-specific targets. Moreover, it may guide optimal clinical CML management. PMID:22157734

  16. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.

    PubMed

    Hughes, Timothy P; Saglio, Giuseppe; Kantarjian, Hagop M; Guilhot, François; Niederwieser, Dietger; Rosti, Gianantonio; Nakaseko, Chiaki; De Souza, Carmino Antonio; Kalaycio, Matt E; Meier, Stephan; Fan, Xiaolin; Menssen, Hans D; Larson, Richard A; Hochhaus, Andreas

    2014-02-27

    We explored the impact of early molecular response (EMR; BCR-ABL ≤10% on the international scale [BCR-ABL(IS)] at 3 or 6 months) on outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with nilotinib or imatinib based on 4 years of follow up in Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients. Patients (n = 846) received nilotinib 300 mg twice daily, nilotinib 400 mg twice daily, or imatinib 400 mg once daily. At 3 months, more patients had EMR failure (ie, BCR-ABL(IS) >10%) on imatinib (33%) than on nilotinib (9%-11%); similarly at 6 months, 16% of patients in the imatinib arm vs 3% and 7% in the nilotinib arms had EMR failure. In all arms, EMR failure was associated with lower rates of molecular response, an increased risk of progression, and lower overall survival compared with EMR achievement. We also analyzed patient and treatment characteristics associated with EMR and found distinct patterns in the nilotinib arms vs the imatinib arm. High Sokal risk score was associated with a high rate of EMR failure on imatinib, but not on nilotinib. In contrast, reduced dose intensity and dose interruptions were strongly associated with EMR failure in nilotinib-treated, but not imatinib-treated, patients. This study is registered at www.clinicaltrials.gov as #NCT00471497.

  17. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.

    PubMed

    Hochhaus, A; Saglio, G; Hughes, T P; Larson, R A; Kim, D-W; Issaragrisil, S; le Coutre, P D; Etienne, G; Dorlhiac-Llacer, P E; Clark, R E; Flinn, I W; Nakamae, H; Donohue, B; Deng, W; Dalal, D; Menssen, H D; Kantarjian, H M

    2016-05-01

    In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a lower risk of progression to accelerated phase/blast crisis (AP/BC) than imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Here, patients' long-term outcomes in ENESTnd are evaluated after a minimum follow-up of 5 years. By 5 years, more than half of all patients in each nilotinib arm (300 mg twice daily, 54%; 400 mg twice daily, 52%) achieved a molecular response 4.5 (MR(4.5); BCR-ABL⩽0.0032% on the International Scale) compared with 31% of patients in the imatinib arm. A benefit of nilotinib was observed across all Sokal risk groups. Overall, safety results remained consistent with those from previous reports. Numerically more cardiovascular events (CVEs) occurred in patients receiving nilotinib vs imatinib, and elevations in blood cholesterol and glucose levels were also more frequent with nilotinib. In contrast to the high mortality rate associated with CML progression, few deaths in any arm were associated with CVEs, infections or pulmonary diseases. These long-term results support the positive benefit-risk profile of frontline nilotinib 300 mg twice daily in patients with CML-CP.

  18. STS-84 Mission Specialist C. Michael Foale in white room

    NASA Technical Reports Server (NTRS)

    1997-01-01

    KENNEDY SPACE CENTER, FLA. -- STS-84 Mission Specialist C. Michael Foale prepares to enter the Space Shuttle Atlantis at Launch Pad 39A with help from white room closeout crew members. The fourth Shuttle mission of 1997 will be the sixth docking of the Space Shuttle with the Russian Space Station Mir. The commander is Charles J. Precourt. The pilot is Eileen Marie Collins. The five mission specialists are C. Michael Foale, Carlos I. Noriega, Edward Tsang Lu, Jean-Francois Clervoy of the European Space Agency and Elena V. Kondakova of the Russian Space Agency. The planned nine-day mission will include the exchange of Foale for U.S. astronaut and Mir 23 crew member Jerry M. Linenger, who has been on Mir since Jan. 15. Linenger transferred to Mir during the last docking mission, STS-81; he will return to Earth on Atlantis. Foale is slated to remain on Mir for about four months until he is replaced in September by STS-86 Mission Specialist Wendy B. Lawrence. During the five days Atlantis is scheduled to be docked with the Mir, the STS-84 crew and the Mir 23 crew, including two Russian cosmonauts, Commander Vasily Tsibliev and Flight Engineer Alexander Lazutkin, will participate in joint experiments. The STS-84 mission also will involve the transfer of more than 7,300 pounds of water, logistics and science equipment to and from the Mir. Atlantis is carrying a nearly 300-pound oxygen generator to replace one of two Mir units which have experienced malfunctions. The oxygen it generates is used for breathing by the Mir crew.

  19. STS-84 Pilot Eileen Marie Collins in white room

    NASA Technical Reports Server (NTRS)

    1997-01-01

    KENNEDY SPACE CENTER, FLA. -- STS-84 Pilot Eileen M. Collins prepares to enter the Space Shuttle Atlantis at Launch Pad 39A with help from white room closeout crew members. The fourth Shuttle mission of 1997 will be the sixth docking of the Space Shuttle with the Russian Space Station Mir. The commander is Charles J. Precourt. The pilot is Eileen Marie Collins. The five mission specialists are C. Michael Foale, Carlos I. Noriega, Edward Tsang Lu, Jean-Francois Clervoy of the European Space Agency and Elena V. Kondakova of the Russian Space Agency. The planned nine-day mission will include the exchange of Foale for U.S. astronaut and Mir 23 crew member Jerry M. Linenger, who has been on Mir since Jan. 15. Linenger transferred to Mir during the last docking mission, STS-81; he will return to Earth on Atlantis. Foale is slated to remain on Mir for about four months until he is replaced in September by STS-86 Mission Specialist Wendy B. Lawrence. During the five days Atlantis is scheduled to be docked with the Mir, the STS-84 crew and the Mir 23 crew, including two Russian cosmonauts, Commander Vasily Tsibliev and Flight Engineer Alexander Lazutkin, will participate in joint experiments. The STS-84 mission also will involve the transfer of more than 7,300 pounds of water, logistics and science equipment to and from the Mir. Atlantis is carrying a nearly 300-pound oxygen generator to replace one of two Mir units which have experienced malfunctions. The oxygen it generates is used for breathing by the Mir crew.

  20. Oral Histories in Meteoritics and Planetary Science - XX: Dale Cruikshank

    NASA Astrophysics Data System (ADS)

    Sears, Derek W. G.

    2013-04-01

    In this interview, Dale Cruikshank (Fig. 1) explains how as an undergraduate at Iowa State University he was a summer student at Yerkes Observatory where he assisted Gerard Kuiper in work on his Photographic Lunar Atlas. Upon completing his degree, Dale went to graduate school at the University of Arizona with Kuiper where he worked on the IR spectroscopy of the lunar surface. After an eventful 1968 trip to Moscow via Prague, during which the Soviets invaded Czechoslovakia, Dale assumed a postdoc position with Vasili Moroz at the Sternberg Astronomical Institute and more observational IR astronomy. Upon returning to the United States and after a year at Arizona, Dale assumed a position at the University of Hawai'i that he held for 17 years. During this period Dale worked with others on thermal infrared determinations of the albedos of small bodies beyond the asteroid Main Belt, leading to the recognition that low-albedo material is prevalent in the outer solar system that made the first report of complex organic solids on a planetary body (Saturn's satellite Iapetus). After moving to Ames Research Center, where he works currently, he continued this work and became involved in many outer solar system missions. Dale has served the community through his involvement in developing national policies for science-driven planetary exploration, being chair of the DPS 1990-1991 and secretary/treasurer for 1982-1985. He served as president of Commission 16 (Physics of Planets) of the IAU (2001-2003). He received the Kuiper prize in 2006.

  1. Testing the taxonomic integrity of Paranthropus boisei sensu stricto.

    PubMed

    Silverman, N; Richmond, B; Wood, B

    2001-06-01

    The craniodental hypodigm of Paranthropus boisei sensu stricto is morphologically distinctive, but it has been suggested that the substantial variation in mandibular and dental size in that hypodigm may exceed that which is reasonable to subsume within a single hominin species. In this study, Fligner and Killeen, coefficient of variation (CV)-based and average taxonomic distance (ATD)-based bootstrap tests, were used to compare variation in size and shape of the mandibular corpus remains attributed to P. boisei s.s. with the variation observed in samples of great apes and modern humans. The degree of size variation in the P. boisei s.s. mandibular hypodigm is never observed in human and chimpanzee samples, is rare in gorillas, but is not uncommon in orangutans. However, the shape variation in the fossil group is comparable to the variation in the extant reference groups. Although the size variation in P. boisei s.s. is substantial, it is exaggerated by the effects of taphonomy. The small mandibles are more often abraded, whereas the large mandibles are more likely to have been infiltrated with matrix. On the basis of the results of this investigation of the mandibular corpus, there are no grounds for rejecting the "single-species" hypothesis for P. boisei s.s. When Sokal and Braumann's adjusted CV values were used to predict the index of sexual dimorphism (ISD) for the P. boisei s.s., despite the substantial geological time embraced by the mandibular corpus hypodigm, the predicted value of lnISD, when corrected for taphonomic factors, is comparable to the sexual dimorphism observed within Gorilla.

  2. A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction

    PubMed Central

    Shinohara, Yoshinori; Takahashi, Naoto; Nishiwaki, Kaichi; Hino, Masayuki; Kashimura, Makoto; Wakita, Hisashi; Hatano, Yoshiaki; Hirasawa, Akira; Nakagawa, Yasuaki; Itoh, Kuniaki; Masuoka, Hidekazu; Aotsuka, Nobuyuki; Matsuura, Yasuhiro; Takahara, Sinobu; Sano, Koji; Kuroki, Jun; Hata, Tomoko; Nakamae, Hirohisa; Mugitani, Atsuko; Nakane, Takahiko; Miyazaki, Yasushi; Niioka, Takenori; Miura, Masatomo; Sawada, Kenichi

    2013-01-01

    Achievement of complete molecular response in patients with chronic phase chronic myeloid leukemia has been recognized as an important milestone in therapy cessation and treatment-free remission; the identification of predictors of complete molecular response in these patients is, therefore, important. This study evaluated complete molecular response rates in imatinib-treated chronic phase chronic myeloid leukemia patients with major molecular response by using the international standardization for quantitative polymerase chain reaction analysis of the breakpoint cluster region-Abelson1 gene. The correlation of complete molecular response with various clinical, pharmacokinetic, and immunological parameters was determined. Complete molecular response was observed in 75/152 patients (49.3%). In the univariate analysis, Sokal score, median time to major molecular response, ABCG2 421C>A, and regulatory T cells were significantly lower in chronic phase chronic myeloid leukemia patients with complete molecular response than in those without complete molecular response. In the multivariate analysis, duration of imatinib treatment (odds ratio: 1.0287, P=0.0003), time to major molecular response from imatinib therapy (odds ratio: 0.9652, P=0.0020), and ABCG2 421C/C genotype (odds ratio: 0.3953, P=0.0284) were independent predictors of complete molecular response. In contrast, number of natural killer cells, BIM deletion polymorphisms, and plasma trough imatinib concentration were not significantly associated with achieving a complete molecular response. Several predictive markers for achieving complete molecular response were identified in this study. According to our findings, some chronic myeloid leukemia patients treated with imatinib may benefit from a switch to second-generation tyrosine kinase inhibitors (ClinicalTrials.gov, UMIN000004935). PMID:23716542

  3. A Single Nucleotide Polymorphism in cBIM Is Associated with a Slower Achievement of Major Molecular Response in Chronic Myeloid Leukaemia Treated with Imatinib

    PubMed Central

    Augis, Vanessa; Airiau, Kelly; Josselin, Marina; Turcq, Béatrice; Mahon, François-Xavier; Belloc, Francis

    2013-01-01

    Purpose BIM is essential for the response to tyrosine-kinase inhibitors (TKI) in chronic myeloid leukaemia (CML) patients. Recently, a deletion polymorphism in intron 2 of the BIM gene was demonstrated to confer an intrinsic TKI resistance in Asian patients. The present study aimed at identifying mutations in the BIM sequence that could lead to imatinib resistance independently of BCR-ABL mutations. Experimental Design BIM coding sequence analysis was performed in 72 imatinib-treated CML patients from a French population of our centre and in 29 healthy controls (reference population) as a case-control study. Real-time quantitative PCR (RT qPCR) was performed to assess Bim expression in our reference population. Results No mutation with amino-acid change was found in the BIM coding sequence. However, we observed a silent single nucleotide polymorphism (SNP) c465C>T (rs724710). A strong statistical link was found between the presence of the T allele and the high Sokal risk group (p = 0.0065). T allele frequency was higher in non responsive patients than in the reference population (p = 0.0049). Similarly, this T allele was associated with the mutation frequency on the tyrosine kinase domain of BCR-ABL (p<0.001) and the presence of the T allele significantly lengthened the time to achieve a major molecular response (MMR). Finally, the presence of the T allele was related to a decreased basal expression of the Bim mRNA in the circulating mononuclear cells of healthy controls. Conclusion These results suggest that the analysis of the c465C>T SNP of BIM could be useful for predicting the outcome of imatinib-treated CML patients. PMID:24223824

  4. Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate

    PubMed Central

    Deb, Pratik; Chakrabarti, Prantar; Chakrabarty, Shila; Aich, Rajarshi; Nath, Uttam; Ray, Siddhartha Sankar; Chaudhuri, Utpal

    2014-01-01

    Context: The exact role of the different transcript variants of BCR-ABL in the pathogenesis of chronic myeloid leukemia (CML) and their impact on prognosis is yet to be definitely enumerated. Aims: In this study, we have tried to correlate the presenting features, risk scores and treatment response with the BCR-ABL variants detected in our patients. Settings and Design: A cross-sectional unicentric hospital-based study on 80 patients diagnosed to have CML by bone marrow cytogenetics and confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR). Materials and Methods: RT-PCR for BCR-ABL was performed on consecutive patients with CML attending the CML clinic from January 2010 to December 2010. The medical charts of these patients were analyzed after a follow-up of 18 months in a retrospective manner. Statistical Analysis: Box plot and histogram was used to see the distribution of variables. t-test was performed to enumerate the difference between risk scores in two populations of patients carrying two different BCR-ABL transcript variants. Results: Nearly 56.25% of patients had b3a2 (e14a2) while 41.25% of patients showed b2a2 (e13a2) transcripts. The rest 2.5% (two patients) expressed the rare e19b2 variant. Patients with b2a2 presented with higher Sokal, Hasford and European Treatment and Outcomes Study score than their b3a2 counterpart. Different parameters such as the platelet count, leukocyte count, hemoglobin and splenomegaly showed a minor difference between the groups. More patients in the b2a2 group achieved complete hematologic response at 3 months, but it was not significant. Conclusions: Patients with b2a2 variant CML tend to present with higher risk score, but do not behave in a vastly different manner than their b3a2 counterparts. PMID:25006280

  5. Évolution de leucémies myéloïdes chroniques sous nilotinib après échec a l'imatinib

    PubMed Central

    Sawadogo, Salifo; Hien, Francis Michel; Ouédraogo, Macaire Sampawendé; Drabo, Youssouf Joseph

    2014-01-01

    C'est une étude observationnelle prospective ouverte: quatre leucémies myéloïdes chroniques résistant ou intolérant à l'Imatinib ont été traitées par le Nilotinib. Elles ont été incluses dans le programme GIPAP et suivies selon les recommandations de “European LeukemiaNet”. Trois ont un score de Sokal de haut risque et une de bas risque. Deux étaient hypertendues. Mises sous Nilotinib, il y a eu deux rémissions cytogénétiques complètes et deux échecs. Le traitement a été interrompu chez les deux rémissions complètes, l'un pour effet secondaire du Nilotinib et l'autre pour changement de pays. Les deux échecs sont dus à des résistances. Le Nilotinib réduisant la fréquence des mutations des leucémies myéloïdes chroniques à haut risque et risque intermédiaire, il serait judicieux d'utiliser ce produit en première intention dans ces cas - ci pour réduire la charge des examens complémentaires. Les pays à bas revenu confrontés à des problèmes de survie ont besoin de la solidarité mondiale pour prendre en charge les leucémies myéloïdes chroniques. PMID:25419280

  6. Relationships in Ananas and other related genera using chloroplast DNA restriction site variation.

    PubMed

    Duval, M F; Buso, G S C; Ferreira, F R; Noyer, J L; Coppens d'Eeckenbrugge, G; Hamon, P; Ferreira, M E

    2003-12-01

    Chloroplast DNA (cpDNA) diversity was examined using PCR-RFLP to study phylogenetic relationships in Ananas and related genera. One hundred fifteen accessions representing the seven Ananas species and seven other Bromelioideae including the neighboring monospecific genus Pseudananas, two Pitcairnioideae, and one Tillandsioideae were included in the study. Eight primers designed from cpDNA were used for generating fragments. Restriction by 18 endonucleases generated 255 variable fragments. Dissimilarities were calculated from the resulting matrix using the Sokal and Michener index and the neighbor-joining method was used to reconstruct the diversity tree. Phylogenetic reconstruction was attempted using Wagner parsimony. Phenetic and cladistic analyses gave consistent results. They confirm the basal position of Bromelia in the Bromelioideae. Ananas and Pseudananas form a monophyletic group, with three strongly supported sub-groups, two of which are geographically consistent. The majority of Ananas parguazensis accessions constitute a northern group restricted to the Rio Negro and Orinoco basins in Brazil. The tetraploid Pseudananas sagenarius joins the diploid Ananas fritzmuelleri to constitute a southern group. The third and largest group, which includes all remaining species plus some accessions of A. parguazensis and intermediate phenotypes, is the most widespread and its distribution overlaps those of the northern and southern groups. Ananas ananassoides is dominant in this sub-group and highly variable. Its close relationship to all cultivated species supports the hypothesis that this species is the wild ancestor of the domesticated pineapple. The data indicate that gene flow is common within this group and scarcer with both the first and second groups. Comparison of cpDNA data with published genomic DNA data point to the hybrid origin of Ananas bracteatus and support the autopolyploidy of Pseudananas. The Ananas-Pseudananas group structure and distribution are

  7. Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.

    PubMed

    Latagliata, Roberto; Stagno, Fabio; Annunziata, Mario; Abruzzese, Elisabetta; Iurlo, Alessandra; Guarini, Attilio; Fava, Carmen; Gozzini, Antonella; Bonifacio, Massimiliano; Sorà, Federica; Leonetti Crescenzi, Sabrina; Bocchia, Monica; Crugnola, Monica; Castagnetti, Fausto; Capodanno, Isabella; Galimberti, Sara; Feo, Costanzo; Porrini, Raffaele; Pregno, Patrizia; Rizzo, Manuela; Antolino, Agostino; Mauro, Endri; Sgherza, Nicola; Luciano, Luigiana; Tiribelli, Mario; Russo Rossi, Antonella; Trawinska, Malgorzata; Vigneri, Paolo; Breccia, Massimo; Rosti, Gianantonio; Alimena, Giuliana

    2016-09-01

    Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we set out a "real-life" cohort of 65 chronic phase CML patients older than 65 years (median age 75.1 years) treated frontline with DAS in 26 Italian centers from June 2012 to June 2015, focusing our attention on toxicity and efficacy data. One third of patients (20/65: 30.7%) had 3 or more comorbidities and required concomitant therapies; according to Sokal classification, 3 patients (4.6%) were low risk, 39 (60.0%) intermediate risk, and 20 (30.8%) high risk, whereas 3 (4.6%) were not classifiable. DAS starting dose was 100 mg once a day in 54 patients (83.0%), whereas 11 patients (17.0%) received less than 100 mg/day. Grade 3/4 hematologic and extrahematologic toxicities were reported in 8 (12.3%) and 12 (18.5%) patients, respectively. Overall, 10 patients (15.4%) permanently discontinued DAS because of toxicities. Pleural effusions (all WHO grades) occurred in 12 patients (18.5%) and in 5 of them occurred during the first 3 months. DAS treatment induced in 60/65 patients (92.3%) a complete cytogenetic response and in 50/65 (76.9%) also a major molecular response. These findings show that DAS might play an important role in the frontline treatment of CML patients >65 years old, proving efficacy and having a favorable safety profile also in elderly subjects with comorbidities.

  8. Cessation of tyrosine kinase inhibitors in patients with chronic-phase chronic myelogenous leukemia following durable complete molecular response: a single center facing the dilemma.

    PubMed

    Iliakis, Theodoros; Papadopoulou, Vasiliki; Diamantopoulos, Panagiotis T; Panayiotidis, Panayiotis; Zervakis, Konstantinos; Giannakopoulou, Nefeli; Tilimidos, Gerassimos; Angelopoulou, Maria; Siakantaris, Marina P; Pangalis, Gerassimos; Mantzourani, Marina; Variami, Eleni; Viniou, Nora Athina

    2013-08-01

    Tyrosine kinase inhibitors (TKIs), namely imatinib mesylate (IM) and recently approved second-generation TKIs dasatinib and nilotinib, are currently considered the treatment of choice for newly-diagnosed chronic phase chronic myelogenous leukemia (CP-CML). Although treatment with TKIs has not yet been proven curative, it certainly accomplishes a sustained control of the disease in the vast majority of patients. More than a decade after the successful launching of IM in first-line treatment of CP-CML and the subsequent introduction of second-generation TKIs in this setting, the question of the possibility of TKI cessation in a specific subset of patients has emerged. Side-effects of TKIs, along with some patients' wish to abandon the drugs and the rising financial burden upon healthcare systems, have led to the dilemma whether IM can be safely withdrawn after achieving deep molecular remissions and which patients are suitable for this discontinuation. We examined the data of our patients with CML in search of potential canditates for cessation of TKI therapy and identified their characteristics. We also performed a thorough review of the relevant literature. Eight out of fifty patients were discriminated on grounds of sustained complete molecular response (CMR) exceeding 12 months, most of them with a low or intermediate Sokal score at diagnosis. The median interval from IM initiation to CMR was almost 2 years and the median duration of detected CMR reached 6.5 years. Based on the promising results of prospective clinical trials reporting successful cessation of treatment with TKIs on selected subgroups of patients, we decided to proceed to interruption of therapy in the specific subset of our patients and closely monitor their response. PMID:23898127

  9. Dasatinib first-line: Multicentric Italian experience outside clinical trials.

    PubMed

    Breccia, Massimo; Stagno, Fabio; Luciano, Luigiana; Abruzzese, Elisabetta; Annunziata, Mario; D'Adda, Mariella; Maggi, Alessandro; Sgherza, Nicola; Russo-Rossi, Antonella; Pregno, Patrizia; Castagnetti, Fausto; Iurlo, Alessandra; Latagliata, Roberto; Cedrone, Michele; Di Renzo, Nicola; Sorà, Federica; Rege-Cambrin, Giovanna; La Nasa, Giorgio; Scortechini, Anna Rita; Greco, Giovanna; Franceschini, Luca; Sica, Simona; Bocchia, Monica; Crugnola, Monica; Orlandi, Esther; Guarini, Attilio; Specchia, Giorgina; Rosti, Gianantonio; Saglio, Giuseppe; Alimena, Giuliana

    2016-01-01

    Dasatinib was approved for the treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients in first line therapy based on the demonstration of efficacy and safety reported in patients enrolled in clinical trials. We describe a multicentric Italian "real-life" experience of dasatinib used as frontline treatment outside clinical trials. One hundred and nine patients (median age 54 years) were treated from January 2012 to December 2013. Increased incidence of high risk patients were detected according to stratification (26% according to Sokal score, 19% according to Euro score and 16% according to EUTOS) when compared to company sponsored studies. Median time from diagnosis to start of dasatinib was 18 days. Ten patients received unscheduled starting dose (6 patients 50mg and 4 patients 80 mg QD), whereas 99 patients started with 100mg QD. At 3 months, 92% of patients achieved a BCR-ABL ratio less than 10%. At 6 months, the rate of CCyR was 91% and the rate of MR3 was 40%, with 8% of the patients reaching MR4.5. Ninety-three patients were evaluable at 12 months: the rate of MR3 was 62%, with MR4.5 being achieved by 19% of the patients. At a median follow-up of 12 months, 27 patients (24.7%) were receiving the drug at reduced dose. Two patients (1.8%) experienced a lymphoid blast crisis and the overall incidence of resistance was 8%. As regards safety, the major side effects recorded were thrombocytopenia, neutropenia and pleural effusions, which occurred in 22%, 10% and 8% of patients, respectively. Present results, achieved in a large cohort of patients treated outside clinical trials, further confirm the efficacy and safety of dasatinib as firstline treatment in CML.

  10. Romance of the three domains: how cladistics transformed the classification of cellular organisms.

    PubMed

    Ho, Chi-Chun; Lau, Susanna K P; Woo, Patrick C Y

    2013-09-01

    Cladistics is a biological philosophy that uses genealogical relationship among species and an inferred sequence of divergence as the basis of classification. This review critically surveys the chronological development of biological classification from Aristotle through our postgenomic era with a central focus on cladistics. In 1957, Julian Huxley coined cladogenesis to denote splitting from subspeciation. In 1960, the English translation of Willi Hennig's 1950 work, Systematic Phylogenetics, was published, which received strong opposition from pheneticists, such as numerical taxonomists Peter Sneath and Robert Sokal, and evolutionary taxonomist, Ernst Mayr, and sparked acrimonious debates in 1960-1980. In 1977-1990, Carl Woese pioneered in using small subunit rRNA gene sequences to delimitate the three domains of cellular life and established major prokaryotic phyla. Cladistics has since dominated taxonomy. Despite being compatible with modern microbiological observations, i.e. organisms with unusual phenotypes, restricted expression of characteristics and occasionally being uncultivable, increasing recognition of pervasiveness and abundance of horizontal gene transfer has challenged relevance and validity of cladistics. The mosaic nature of eukaryotic and prokaryotic genomes was also gradually discovered. In the mid-2000s, high-throughput and whole-genome sequencing became routine and complex geneologies of organisms have led to the proposal of a reticulated web of life. While genomics only indirectly leads to understanding of functional adaptations to ecological niches, computational modeling of entire organisms is underway and the gap between genomics and phenetics may soon be bridged. Controversies are not expected to settle as taxonomic classifications shall remain subjective to serve the human scientist, not the classified.

  11. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group

    PubMed Central

    Cervantes, Francisco; López-Garrido, Pilar; Montero, María-Isabel; Jonte, Fermín; Martínez, Jesús; Hernández-Boluda, Juan-Carlos; Calbacho, María; Sureda, Anna; Pérez-Rus, Gloria; Nieto, José B.; Pérez-López, Cristina; Román-Gómez, José; González, Marcos; Pereira, Arturo; Colomer, Dolors

    2010-01-01

    Background Despite the favorable results of imatinib front line in chronic-phase chronic myeloid leukemia there is room for improvement. Design and Methods Early intervention during imatinib therapy was undertaken in 210 adults with chronic-phase chronic myeloid leukemia less than three months from diagnosis (Sokal high risk: 16%). Patients received imatinib 400 mg/day. At three months, dose was increased if complete hematologic response was not achieved. At six months, patients in complete cytogenetic response were kept on 400 mg and the remainder randomized to higher imatinib dose or 400 mg plus interferon-alfa. At 18 months, randomized patients were switched to a 2nd generation tyrosine kinase inhibitor if not in complete cytogenetic response and imatinib dose increased in non-randomized patients not in major molecular response. Results Seventy-two percent of patients started imatinib within one month from diagnosis. Median follow-up is 50.5 (range: 1.2–78) months. At three months 4 patients did not have complete hematologic response; at six months 73.8% were in complete cytogenetic response; among the remainder, 9 could not be randomized (toxicity or consent withdrawal), 17 were assigned to high imatinib dose, and 15 to 400 mg + interferon-alpha. The low number of randomized patients precluded comparison between the two arms. Cumulative response at three years was: complete hematologic response 98.6%, complete cytogenetic response 90% and major molecular response 82%. On an intention-to-treat basis, complete cytogenetic response was 78.8% at 18 months. At five years, survival was 97.5%, survival free from accelerated/blastic phase 94.3%, failure free survival 82.5%, and event free survival (including permanent imatinib discontinuation) 71.5%. Conclusions These results indicate the benefit of early intervention during imatinib therapy (ClinicalTrials.gov Identifier: NCT00390897). PMID:20220063

  12. The applicability of certain Monte Carlo methods to the analysis of interacting polymers

    SciTech Connect

    Krapp, D.M. Jr.

    1998-05-01

    The authors consider polymers, modeled as self-avoiding walks with interactions on a hexagonal lattice, and examine the applicability of certain Monte Carlo methods for estimating their mean properties at equilibrium. Specifically, the authors use the pivoting algorithm of Madras and Sokal and Metroplis rejection to locate the phase transition, which is known to occur at {beta}{sub crit} {approx} 0.99, and to recalculate the known value of the critical exponent {nu} {approx} 0.58 of the system for {beta} = {beta}{sub crit}. Although the pivoting-Metropolis algorithm works well for short walks (N < 300), for larger N the Metropolis criterion combined with the self-avoidance constraint lead to an unacceptably small acceptance fraction. In addition, the algorithm becomes effectively non-ergodic, getting trapped in valleys whose centers are local energy minima in phase space, leading to convergence towards different values of {nu}. The authors use a variety of tools, e.g. entropy estimation and histograms, to improve the results for large N, but they are only of limited effectiveness. Their estimate of {beta}{sub crit} using smaller values of N is 1.01 {+-} 0.01, and the estimate for {nu} at this value of {beta} is 0.59 {+-} 0.005. They conclude that even a seemingly simple system and a Monte Carlo algorithm which satisfies, in principle, ergodicity and detailed balance conditions, can in practice fail to sample phase space accurately and thus not allow accurate estimations of thermal averages. This should serve as a warning to people who use Monte Carlo methods in complicated polymer folding calculations. The structure of the phase space combined with the algorithm itself can lead to surprising behavior, and simply increasing the number of samples in the calculation does not necessarily lead to more accurate results.

  13. Romance of the three domains: how cladistics transformed the classification of cellular organisms.

    PubMed

    Ho, Chi-Chun; Lau, Susanna K P; Woo, Patrick C Y

    2013-09-01

    Cladistics is a biological philosophy that uses genealogical relationship among species and an inferred sequence of divergence as the basis of classification. This review critically surveys the chronological development of biological classification from Aristotle through our postgenomic era with a central focus on cladistics. In 1957, Julian Huxley coined cladogenesis to denote splitting from subspeciation. In 1960, the English translation of Willi Hennig's 1950 work, Systematic Phylogenetics, was published, which received strong opposition from pheneticists, such as numerical taxonomists Peter Sneath and Robert Sokal, and evolutionary taxonomist, Ernst Mayr, and sparked acrimonious debates in 1960-1980. In 1977-1990, Carl Woese pioneered in using small subunit rRNA gene sequences to delimitate the three domains of cellular life and established major prokaryotic phyla. Cladistics has since dominated taxonomy. Despite being compatible with modern microbiological observations, i.e. organisms with unusual phenotypes, restricted expression of characteristics and occasionally being uncultivable, increasing recognition of pervasiveness and abundance of horizontal gene transfer has challenged relevance and validity of cladistics. The mosaic nature of eukaryotic and prokaryotic genomes was also gradually discovered. In the mid-2000s, high-throughput and whole-genome sequencing became routine and complex geneologies of organisms have led to the proposal of a reticulated web of life. While genomics only indirectly leads to understanding of functional adaptations to ecological niches, computational modeling of entire organisms is underway and the gap between genomics and phenetics may soon be bridged. Controversies are not expected to settle as taxonomic classifications shall remain subjective to serve the human scientist, not the classified. PMID:23873078

  14. Dasatinib first-line: Multicentric Italian experience outside clinical trials.

    PubMed

    Breccia, Massimo; Stagno, Fabio; Luciano, Luigiana; Abruzzese, Elisabetta; Annunziata, Mario; D'Adda, Mariella; Maggi, Alessandro; Sgherza, Nicola; Russo-Rossi, Antonella; Pregno, Patrizia; Castagnetti, Fausto; Iurlo, Alessandra; Latagliata, Roberto; Cedrone, Michele; Di Renzo, Nicola; Sorà, Federica; Rege-Cambrin, Giovanna; La Nasa, Giorgio; Scortechini, Anna Rita; Greco, Giovanna; Franceschini, Luca; Sica, Simona; Bocchia, Monica; Crugnola, Monica; Orlandi, Esther; Guarini, Attilio; Specchia, Giorgina; Rosti, Gianantonio; Saglio, Giuseppe; Alimena, Giuliana

    2016-01-01

    Dasatinib was approved for the treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients in first line therapy based on the demonstration of efficacy and safety reported in patients enrolled in clinical trials. We describe a multicentric Italian "real-life" experience of dasatinib used as frontline treatment outside clinical trials. One hundred and nine patients (median age 54 years) were treated from January 2012 to December 2013. Increased incidence of high risk patients were detected according to stratification (26% according to Sokal score, 19% according to Euro score and 16% according to EUTOS) when compared to company sponsored studies. Median time from diagnosis to start of dasatinib was 18 days. Ten patients received unscheduled starting dose (6 patients 50mg and 4 patients 80 mg QD), whereas 99 patients started with 100mg QD. At 3 months, 92% of patients achieved a BCR-ABL ratio less than 10%. At 6 months, the rate of CCyR was 91% and the rate of MR3 was 40%, with 8% of the patients reaching MR4.5. Ninety-three patients were evaluable at 12 months: the rate of MR3 was 62%, with MR4.5 being achieved by 19% of the patients. At a median follow-up of 12 months, 27 patients (24.7%) were receiving the drug at reduced dose. Two patients (1.8%) experienced a lymphoid blast crisis and the overall incidence of resistance was 8%. As regards safety, the major side effects recorded were thrombocytopenia, neutropenia and pleural effusions, which occurred in 22%, 10% and 8% of patients, respectively. Present results, achieved in a large cohort of patients treated outside clinical trials, further confirm the efficacy and safety of dasatinib as firstline treatment in CML. PMID:26643920

  15. Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.

    PubMed

    Latagliata, Roberto; Stagno, Fabio; Annunziata, Mario; Abruzzese, Elisabetta; Iurlo, Alessandra; Guarini, Attilio; Fava, Carmen; Gozzini, Antonella; Bonifacio, Massimiliano; Sorà, Federica; Leonetti Crescenzi, Sabrina; Bocchia, Monica; Crugnola, Monica; Castagnetti, Fausto; Capodanno, Isabella; Galimberti, Sara; Feo, Costanzo; Porrini, Raffaele; Pregno, Patrizia; Rizzo, Manuela; Antolino, Agostino; Mauro, Endri; Sgherza, Nicola; Luciano, Luigiana; Tiribelli, Mario; Russo Rossi, Antonella; Trawinska, Malgorzata; Vigneri, Paolo; Breccia, Massimo; Rosti, Gianantonio; Alimena, Giuliana

    2016-09-01

    Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we set out a "real-life" cohort of 65 chronic phase CML patients older than 65 years (median age 75.1 years) treated frontline with DAS in 26 Italian centers from June 2012 to June 2015, focusing our attention on toxicity and efficacy data. One third of patients (20/65: 30.7%) had 3 or more comorbidities and required concomitant therapies; according to Sokal classification, 3 patients (4.6%) were low risk, 39 (60.0%) intermediate risk, and 20 (30.8%) high risk, whereas 3 (4.6%) were not classifiable. DAS starting dose was 100 mg once a day in 54 patients (83.0%), whereas 11 patients (17.0%) received less than 100 mg/day. Grade 3/4 hematologic and extrahematologic toxicities were reported in 8 (12.3%) and 12 (18.5%) patients, respectively. Overall, 10 patients (15.4%) permanently discontinued DAS because of toxicities. Pleural effusions (all WHO grades) occurred in 12 patients (18.5%) and in 5 of them occurred during the first 3 months. DAS treatment induced in 60/65 patients (92.3%) a complete cytogenetic response and in 50/65 (76.9%) also a major molecular response. These findings show that DAS might play an important role in the frontline treatment of CML patients >65 years old, proving efficacy and having a favorable safety profile also in elderly subjects with comorbidities. PMID:27659013

  16. A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction.

    PubMed

    Shinohara, Yoshinori; Takahashi, Naoto; Nishiwaki, Kaichi; Hino, Masayuki; Kashimura, Makoto; Wakita, Hisashi; Hatano, Yoshiaki; Hirasawa, Akira; Nakagawa, Yasuaki; Itoh, Kuniaki; Masuoka, Hidekazu; Aotsuka, Nobuyuki; Matsuura, Yasuhiro; Takahara, Sinobu; Sano, Koji; Kuroki, Jun; Hata, Tomoko; Nakamae, Hirohisa; Mugitani, Atsuko; Nakane, Takahiko; Miyazaki, Yasushi; Niioka, Takenori; Miura, Masatomo; Sawada, Kenichi

    2013-09-01

    Achievement of complete molecular response in patients with chronic phase chronic myeloid leukemia has been recognized as an important milestone in therapy cessation and treatment-free remission; the identification of predictors of complete molecular response in these patients is, therefore, important. This study evaluated complete molecular response rates in imatinib-treated chronic phase chronic myeloid leukemia patients with major molecular response by using the international standardization for quantitative polymerase chain reaction analysis of the breakpoint cluster region-Abelson1 gene. The correlation of complete molecular response with various clinical, pharmacokinetic, and immunological parameters was determined. Complete molecular response was observed in 75/152 patients (49.3%). In the univariate analysis, Sokal score, median time to major molecular response, ABCG2 421C>A, and regulatory T cells were significantly lower in chronic phase chronic myeloid leukemia patients with complete molecular response than in those without complete molecular response. In the multivariate analysis, duration of imatinib treatment (odds ratio: 1.0287, P=0.0003), time to major molecular response from imatinib therapy (odds ratio: 0.9652, P=0.0020), and ABCG2 421C/C genotype (odds ratio: 0.3953, P=0.0284) were independent predictors of complete molecular response. In contrast, number of natural killer cells, BIM deletion polymorphisms, and plasma trough imatinib concentration were not significantly associated with achieving a complete molecular response. Several predictive markers for achieving complete molecular response were identified in this study. According to our findings, some chronic myeloid leukemia patients treated with imatinib may benefit from a switch to second-generation tyrosine kinase inhibitors (ClinicalTrials.gov, UMIN000004935).

  17. Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil

    PubMed Central

    Rego, Monica Napoleão Fortes; Metze, Konradin; Lorand-Metze, Irene

    2015-01-01

    OBJECTIVES: In Brazil, imatinib mesylate is supplied as the first-line therapy for chronic myeloid leukemia in the chronic phase through the public universal healthcare program, Sistema Único de Saúde (SUS). We studied the socio-demographic factors that influenced therapy success in a population in the northeast region of Brazil. METHODS: Patients with chronic myeloid leukemia from the state of Piauí were treated in only one reference center. Diagnosis was based on WHO 2008 criteria. Risk was assessed by Sokal, Hasford and EUTOS scores. Patients received 400 mg imatinib daily. We studied the influence of the following factors on the achievement of complete cytogenetic response within one year of treatment: age, clinical risk category, time interval between diagnosis and the start of imatinib treatment, geographic distance from the patient's home to the hospital, years of formal education and monthly income. RESULTS: Among 103 patients studied, the median age was 42 years; 65% of the patients had 2-9 years of formal education, and the median monthly income was approximately 100 US$. Imatinib was started in the first year after diagnosis (early chronic phase) in 69 patients. After 12 months of treatment, 68 patients had a complete cytogenetic response. The Hasford score, delay to start imatinib and years of formal education influenced the attainment of a complete cytogenetic response, whereas income and the distance from the home to the healthcare facility did not. CONCLUSION: Patients require additional healthcare information to better understand the importance of long-term oral anticancer treatment and to improve their compliance with the treatment. PMID:26039947

  18. PREFACE: 2nd International Conference and Young Scientist School ''Magnetic resonance imaging in biomedical research''

    NASA Astrophysics Data System (ADS)

    Naumova, A. V.; Khodanovich, M. Y.; Yarnykh, V. L.

    2016-02-01

    The Second International Conference and Young Scientist School ''Magnetic resonance imaging in biomedical research'' was held on the campus of the National Research Tomsk State University (Tomsk, Russia) on September 7-9, 2015. The conference was focused on magnetic resonance imaging (MRI) applications for biomedical research. The main goal was to bring together basic scientists, clinical researchers and developers of new MRI techniques to bridge the gap between clinical/research needs and advanced technological solutions. The conference fostered research and development in basic and clinical MR science and its application to health care. It also had an educational purpose to promote understanding of cutting-edge MR developments. The conference provided an opportunity for researchers and clinicians to present their recent theoretical developments, practical applications, and to discuss unsolved problems. The program of the conference was divided into three main topics. First day of the conference was devoted to educational lectures on the fundamentals of MRI physics and image acquisition/reconstruction techniques, including recent developments in quantitative MRI. The second day was focused on developments and applications of new contrast agents. Multinuclear and spectroscopic acquisitions as well as functional MRI were presented during the third day of the conference. We would like to highlight the main developments presented at the conference and introduce the prominent speakers. The keynote speaker of the conference Dr. Vasily Yarnykh (University of Washington, Seattle, USA) presented a recently developed MRI method, macromolecular proton fraction (MPF) mapping, as a unique tool for modifying image contrast and a unique tool for quantification of the myelin content in neural tissues. Professor Yury Pirogov (Lomonosov Moscow State University) described development of new fluorocarbon compounds and applications for biomedicine. Drs. Julia Velikina and Alexey

  19. Non-Invasive Assessment of Susceptibility to Ventricular Arrhythmias During Simulated Microgravity

    NASA Technical Reports Server (NTRS)

    Cohen, Richard J.

    1999-01-01

    The Cardiovascular Alterations Team is currently conducting studies to determine what alterations in hemodynamic regulation result from sixteen days of simulated microgravity exposure in normal human subjects. In this project we make additional measurements on these same study subjects in order to determine whether there is an increase in susceptibility to ventricular arrhythmias resulting from simulated microgravity exposure. Numerous anecdotal and documented reports from the past 30 years suggest that the incidence of ventricular arrhythmias among astronauts is increased during space flight. For example, documented runs of ventricular tachycardia have been recorded from crew members of Skylab and Mir, there was much attention given by the lay press to Mir Commander Vasily Tslbliyev's complaints of heart rhythm irregularities in July of 1997, and cardiovascular mechanisms may have been causal in the recent death of an experimental primate shortly after return from space. In 1986, a Mir cosmonaut, Alexander Laveikin, was brought home and replaced with an alternate cosmonaut as a result of cardiac dysrhythmias that began during extravehicular activity. Furthermore, at a joint NASA/NSBRI workshop held in January 1998, cardiac arrhythmias were identified as the highest priority cardiovascular risk to a human Mars mission. Despite the evidence for the risk of a potentially lethal arrhythmia resulting from microgravity exposure, the effects of space flight and the associated physiologic stresses on cardiac conduction processes are not known, and an increase in cardiac susceptibility to arrhythmias has never been quantified. In this project, we are determining whether simulated space flight increases the risk of developing life-threatening heart rhythm disturbances such as sustained ventricular tachycardia (defined as ventricular tachycardia lasting at least 30 seconds or resulting in hemodynamic collapse) and ventricular fibrillation. We are obtaining measures of

  20. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.

    PubMed

    Breccia, Massimo; Luciano, Luigiana; Latagliata, Roberto; Castagnetti, Fausto; Ferrero, Dario; Cavazzini, Francesco; Trawinska, Malgorzata Monica; Annunziata, Mario; Stagno, Fabio; Tiribelli, Mario; Binotto, Gianni; Crisà, Elena; Musto, Pellegrino; Gozzini, Antonella; Cavalli, Laura; Montefusco, Enrico; Iurlo, Alessandra; Russo, Sabina; Cedrone, Michele; Rossi, Antonella Russo; Pregno, Patrizia; Endri, Mauro; Spadea, Antonio; Molica, Matteo; Giglio, Gianfranco; Celesti, Francesca; Sorà, Federica; Storti, Sergio; D'Addosio, Ada; Cambrin, Giovanna Rege; Isidori, Alessandro; Sica, Simona; Abruzzese, Elisabetta; Speccha, Giorgina; Rosti, Gianantonio; Alimena, Giuliana

    2014-10-01

    We applied Charlson comorbidity index (CCI) stratification on a large cohort of chronic myeloid leukemia (CML) very elderly patients (>75 years) treated with imatinib, in order to observe the impact of concomitant diseases on both compliance and outcome. One hundred and eighty-one patients were recruited by 21 Italian centers. There were 95 males and 86 females, median age 78.6 years (range 75-93.6). According to Sokal score, 106 patients were classified as intermediate risk and 55 as high risk (not available in 20 patients). According to CCI stratification, 71 patients had score 0 and 110 a score ≥ 1. Imatinib standard dose was reduced at start of therapy (200-300 mg/day) in 68 patients independently from the evaluation of baseline comorbidities, but based only on physician judgement: 43.6% of these patients had score 0 compared to 34% of patients who had score ≥ 1. Significant differences were found in terms of subsequent dose reduction (39% of patients with score 0 compared to 53% of patients with score ≥ 1) and in terms of drug discontinuation due to toxicity (35% of patients with score 0 vs 65% of patients with score ≥ 1). We did not find significant differences as regards occurrence of hematologic side effects, probably as a consequence of the initial dose reduction: 39% of patients with score 0 experienced grade 3/4 hematologic toxicity (most commonly anemia) compared to 42% of patients with score ≥ 1. Independently from the initial dose, comorbidities again did not have an impact on development of grade 3/4 non-hematologic side effects (most commonly skin rash, muscle cramps and fluid retention): 62% of patients with score 0 compared to 52.5% of patients with score ≥ 1. Notwithstanding the reduced dose and the weight of comorbidities we did not find significant differences but only a trend in terms of efficacy: 66% of patients with score 0 achieved a CCyR compared to 54% of patients with score ≥ 1. Comorbidities appeared to have an impact on

  1. Phylogeny of plastids based on cladistic analysis of gene loss inferred from complete plastid genome sequences.

    PubMed

    Nozaki, Hisayoshi; Ohta, Njij; Matsuzaki, Motomichi; Misumi, Osami; Kuroiwa, Tsuneyoshi

    2003-10-01

    Based on the recent hypothesis on the origin of eukaryotic phototrophs, red algae, green plants, and glaucophytes constitute the "primary photosynthetic eukaryotes" (whose plastids may have originated directly from a cyanobacterium-like prokaryote via primary endosymbiosis), whereas the plastids of other lineages of eukaryotic phototrophs appear to be the result of secondary or tertiary endosymbiotic events (involving a phototrophic eukaryote and a host cell). Although phylogenetic analyses using multiple plastid genes from a wide range of eukaryotic lineages have been carried out, some of the major phylogenetic relationships of plastids remain ambiguous or conflict between different phylogenetic methods used for nucleotide or amino acid substitutions. Therefore, an alternative methodology to infer the plastid phylogeny is needed. Here, we carried out a cladistic analysis of the "loss of plastid genes" after primary endosymbiosis using complete plastid genome sequences from a wide range of eukaryotic phototrophs. Since it is extremely unlikely that plastid genes are regained during plastid evolution, we used the irreversible Camin-Sokal model for our cladistic analysis of the loss of plastid genes. The cladistic analysis of the 274 plastid protein-coding genes resolved the 20 operational taxonomic units representing a wide range of eukaryotic lineages (including three secondary plastid-containing groups) into two large monophyletic groups with high bootstrap values: one corresponded to the red lineage and the other consisted of a large clade composed of the green lineage (green plants and Euglena) and the basal glaucophyte plastid. Although the sister relationship between the green lineage and the Glaucophyta was not resolved in recent phylogenetic studies using amino acid substitutions from multiple plastid genes, it is consistent with the rbcL gene phylogeny and with a recent phylogenetic study using multiple nuclear genes. In addition, our analysis robustly

  2. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.

    PubMed

    Breccia, Massimo; Luciano, Luigiana; Latagliata, Roberto; Castagnetti, Fausto; Ferrero, Dario; Cavazzini, Francesco; Trawinska, Malgorzata Monica; Annunziata, Mario; Stagno, Fabio; Tiribelli, Mario; Binotto, Gianni; Crisà, Elena; Musto, Pellegrino; Gozzini, Antonella; Cavalli, Laura; Montefusco, Enrico; Iurlo, Alessandra; Russo, Sabina; Cedrone, Michele; Rossi, Antonella Russo; Pregno, Patrizia; Endri, Mauro; Spadea, Antonio; Molica, Matteo; Giglio, Gianfranco; Celesti, Francesca; Sorà, Federica; Storti, Sergio; D'Addosio, Ada; Cambrin, Giovanna Rege; Isidori, Alessandro; Sica, Simona; Abruzzese, Elisabetta; Speccha, Giorgina; Rosti, Gianantonio; Alimena, Giuliana

    2014-10-01

    We applied Charlson comorbidity index (CCI) stratification on a large cohort of chronic myeloid leukemia (CML) very elderly patients (>75 years) treated with imatinib, in order to observe the impact of concomitant diseases on both compliance and outcome. One hundred and eighty-one patients were recruited by 21 Italian centers. There were 95 males and 86 females, median age 78.6 years (range 75-93.6). According to Sokal score, 106 patients were classified as intermediate risk and 55 as high risk (not available in 20 patients). According to CCI stratification, 71 patients had score 0 and 110 a score ≥ 1. Imatinib standard dose was reduced at start of therapy (200-300 mg/day) in 68 patients independently from the evaluation of baseline comorbidities, but based only on physician judgement: 43.6% of these patients had score 0 compared to 34% of patients who had score ≥ 1. Significant differences were found in terms of subsequent dose reduction (39% of patients with score 0 compared to 53% of patients with score ≥ 1) and in terms of drug discontinuation due to toxicity (35% of patients with score 0 vs 65% of patients with score ≥ 1). We did not find significant differences as regards occurrence of hematologic side effects, probably as a consequence of the initial dose reduction: 39% of patients with score 0 experienced grade 3/4 hematologic toxicity (most commonly anemia) compared to 42% of patients with score ≥ 1. Independently from the initial dose, comorbidities again did not have an impact on development of grade 3/4 non-hematologic side effects (most commonly skin rash, muscle cramps and fluid retention): 62% of patients with score 0 compared to 52.5% of patients with score ≥ 1. Notwithstanding the reduced dose and the weight of comorbidities we did not find significant differences but only a trend in terms of efficacy: 66% of patients with score 0 achieved a CCyR compared to 54% of patients with score ≥ 1. Comorbidities appeared to have an impact on

  3. How much soil do young children ingest: an epidemiologic study.

    PubMed

    Calabrese, E J; Barnes, R; Stanek, E J; Pastides, H; Gilbert, C E; Veneman, P; Wang, X R; Lasztity, A; Kostecki, P T

    1989-10-01

    Sixty-four children aged 1-4 years were evaluated for the extent to which they ingest soil. The study followed the soil tracer methodology of S. Binder, D. Sokal, and D. Maughan (1986, Arch. Environ. Health, 41, 341-345). However, the present study included a number of modifications from the Binder et al. study. The principal new features were (1) increasing the tracer elements from three to eight; (2) using a mass-balance approach so that the contribution of food and medicine ingestion would be considered; (3) extending the period of observation from 3 days to 8 days; and (4) validating the methodology by having adult volunteers ingest known amounts of soil in a mass-balance validation study. The principal findings reveal the following. (1) The adult study confirmed the validity of the tracer methodology to estimate soil ingestion. (2) Of the eight tracers employed in the adult study, only Al, Si, and Y provided sufficient recovery data that was directly acceptably stable and reliable. (3) If food ingestion determinations were taken into consideration, the median estimates of soil ingestion from the eight tracers ranged from a low of 9 mg/day (Y) to a high of 96 mg/day (V); the median values of Al, Si, and Y, the three most reliable tracers, ranged from 9 mg/day to 40 mg/day. (4) One child had soil ingestion values ranging from 5 to 8 g/day, depending on the tracer. (5) If food ingestion had not been considered, the estimates of soil ingestion would have increased about two- to sixfold, depending on the tracer with Ti and Y being most affected by food intake. (6) Since soil and dust samples did not significantly differ in their levels of tracer elements, no reliable differentiation between the contribution of ingestion of dust and soil could be made. (7) These findings are generally consistent with the previously reported findings of Binder et al. (1986) and P. Clausing, B. Brunekreff, and J.H. van Wijnen (1987, Int. Arch. Occup. Med., 59, 73) if these latter

  4. Electrochemical oxygen pumps. Final CRADA report.

    SciTech Connect

    Carter, J. D. Noble, J.

    2009-10-01

    All tasks of the Work Plan of ISTC Project 2277p have been completed, thus: (1) techniques of chemical synthesis were developed for more than ten recipes of electrolyte based on cerium oxide doped with 20 mole% of gadolinium (CeGd)O{sub 2}, doped by more than 10 oxide systems including 6 recipes in addition to the Work Plan; (2) electric conductivity and mechanical strength of CeGd specimens with additions of oxide systems were performed, two candidate materials for the electrolyte of electrochemical oxygen pump (pure CeGd and CeGd doped by 0.2 wt% of a transition metal) were chosen; (3) extended studies of mechanical strength of candidate material specimens were performed at room temperature and at 400, 600, 800 C; (4) fixtures for determination of mechanical strength of tubes by external pressure above 40 atmospheres at temperature up to 700 C were developed and fabricated; and (5) technology of slip casting of tubes from pure (Ce,Gd)O{sub 2} and of (Ce,Gd)O{sub 2} doped by 0.2 wt% of a transition metal, withstanding external pressure of minimum 40 atmospheres at temperature up to 700 C was developed, a batch of tubes was sent for testing to Argonne National Laboratory; (6) technology of making nanopowder from pure (Ce,Gd)O{sub 2} was developed based on chemical synthesis and laser ablation techniques, a batch of nanopowder with the weight 1 kg was sent for testing to Argonne National Laboratory; (7) a business plan for establishing a company for making powders of materials for electrochemical oxygen pump was developed; and (8) major results obtained within the Project were reported at international conferences and published in the Russian journal Electrochemistry. In accordance with the Work Plan a business trip of the following project participants was scheduled for April 22-29, 2006, to Tonawanda, NY, USA: Manager Victor Borisov; Leader of technology development Gennady Studenikin; Leader of business planning Elena Zadorozhnaya; Leader of production Vasily

  5. New method to determine initial surface water displacement at tsunami source

    NASA Astrophysics Data System (ADS)

    Lavrentyev, Mikhail; Romanenko, Alexey; Tatarintsev, Pavel

    2013-04-01

    earthquake. However, today it is not yet possible. Ground-based sea radars. This is an effective tool for direct measurement of tsunami wave. At the same time, the wave is measured at a rather narrow area in front of the radar and does not include information about neighboring parts of the wave. Direct measurement of tsunami wave at deep water [2]. Today, this technology is certainly among the most useful and promising. The DART II® system consists of a seafloor bottom pressure recording (BPR) system, capable of detecting tsunamis as small as 1 cm, and a moored surface buoy for real-time communications. We focus our research on improving the later method, direct measurement of tsunami wave at deep water. We suggest the new way to analyze DART data, modifying the methodology originally proposed by V. Titov. Smaller system of unit sources [3] should be considered to approximate all typical shapes of initial disturbance by several suitable basis functions. To successfully implement it, performance of data analysis should be dramatically improved. This could be done by using a signal orthogonalization procedure for considered system of unit sources and calculation of Fourier coefficients of the measured time series with respect to orthogonal basis. The approach suggested was used as a part of computerized workstation for tsunami hazard monitoring [5-6]. National Oceanic and Atmospheric Administration Center for Tsunami Research. URL: http://nctr.pmel.noaa.gov/honshu20110311/ National Data Buoy Center. URL: http://www.ndbc.noaa.gov/dart.shtml National Oceanic and Atmospheric Administration Center for Tsunami Research. URL: http://sift.pmel.noaa.gov/thredds/dodsC/uncompressed/ National Oceanic and Atmospheric Administration Center for Tsunami Research. URL: http://nctr.pmel.noaa.gov/model.html Alexey Romanenko, Mikhail Lavrentiev-jr, Vasily Titov, "Modern Architecture for Tsunami Hazard Mitigation" // Asia Oceania Geosciences Society (AOGS-2012), ISBN 978-981-07-2049-0 Mikhail

  6. Deep Ocean Tsunami Waves off the Sri Lankan Coast

    NASA Technical Reports Server (NTRS)

    2004-01-01

    fully understand the dynamics. Examination of other MISR images of this area, taken under similar illumination conditions, has not uncovered any surface patterns resembling those seen here. This image is an example of how MISR's multi-angular capability provides unique information for understanding how tsunamis propagate. Another application of MISR data enabled scientists to measure the motion of breaking tsunami waves along the eastern shores of Andhra Pradesh, India. The Multi-angle Imaging SpectroRadiometer observes the daylit Earth continuously and every 9 days views the entire globe between 82 degrees North and 82 degrees South latitude. These data products were generated from a portion of the imagery acquired during Terra orbit 26720 and utilize data from within blocks 85 to 86 within World Reference System-2 path 142. MISR was built and is managed by NASA's Jet Propulsion Laboratory, Pasadena, CA, for NASA's Office of Earth Science, Washington, DC. The Terra satellite is managed by NASA's Goddard Space Flight Center, Greenbelt, MD. Image courtesy NASA/GSFC/LaRC/JPL, MISR Team. Text by Clare Averill (Raytheon ITSS/JPL); Michael Garay and David J. Diner (JPL, California Institute of Technology); and Vasily Titov (NOAA/Pacific Marine Environmental Laboratory and University of Washington/Joint Institute for the Study of the Atmosphere and Oceans).

  7. EDITORIAL: Focus on Cloaking and Transformation Optics

    NASA Astrophysics Data System (ADS)

    Leonhardt, Ulf; Smith, David R.

    2008-11-01

    coordinate transformations. If the coordinates they conjure up run backwards one gets negative refraction, if they exclude some region of space one makes anything inside invisible [4]. In physics, general relativity has honed the theoretical tools for understanding curved space and curved-coordinate transformations. In transformation optics, general relativity has become a theoretical tool for solving practical engineering problems [4]. What an unorthodox connection! This focus issue represents a snapshot of this rapidly developing research area. It is not restricted to optics or electromagnetism, though. Metamaterials for acoustics also exist and can be applied in ways similar to optical metamaterials. So transformation optics not only attracts an unusual mix of scientists, but also spans a range of applications in optics and beyond. Transformation optics has the potential to transform optics, for example by visualizing invisibility and making materials beyond materials—metamaterials. But before we transgress the boundaries to the hermeneutics of transformation optics [5], let the papers speak for themselves. References [1] Yao J, Liu Z, Liu Y, Wang Y, Sun C, Bartal G, Stacy A M and Zhang X 2008 Science 321 930 [2] Valentine J, Zhang S, Zentgraf T, Ulin-Avila E, Genov D A, Bartal G and Zhang X 2008 Nature 455 376 [3] Schurig D, Mock J J, Justice B J, Cummer S A, Pendry J B, Starr A F and Smith D R 2006 Science 314 977 [4] Leonhardt U and Philbin T G 2006 New J. Phys. 8 247 [5] Sokal A D 1996 Social Text 14(46/47) 217 Focus on Cloaking and Transformation Optics Contents Transformation optics for the full dielectric electromagnetic cloak and metal-dielectric planar hyperlens D P Gaillot, C Croënne, F Zhang and D Lippens Transmutation of singularities in optical instruments Tomáš Tyc and Ulf Leonhardt Electromagnetic cloaking with canonical spiral inclusions K Guven, E Saenz, R Gonzalo, E Ozbay and S Tretyakov Theory and potentials of multi-layered plasmonic covers for

  8. Renormalization group calculation of the universal critical exponents of a polymer molecule

    NASA Astrophysics Data System (ADS)

    Belohorec, Peter

    , obtained as a fit to both the MC and exact data, allowed us to generate recursively all values of Rsbsp{N}{2}(w) and Asb2,sb{N}(w) for chains of length N = 2× 2sp{n} or N = 3× 2sp{n} and for any value of DJ parameter w using the inverse of the effective exponent transformation. This was used to evaluate the leading non-universal scaling amplitudes asb{R}(w),\\ asb{A}(w) and the non-universal correction to scaling amplitudes bsb{R}(w),\\ bsb{A}(w) as well as to compare our results to those of others. In the self-avoiding walk limit (w = 1) our generated data for Rsbsp{N}{2}(1) and Asb{2,N}(1) very well agree with the MC data of Li et al. (Li B., Madras N., and Sokal A. D. (1995). J. Stat. Phys. 80, 661). Also in the two-parameter model limit (w-> 0 and N->infty with z~ wNsp{1/2} = const.) our result for the expansion factor alphasbsp{R}{2}(z) agrees very well with the previous high precision estimate of des Cloizeaux et al. (des Cloizeaux J., Conte R. and Jannik G. (1985). Journal de Physique Lettres 46, L-595) in the range z≤ 1. The two-parameter result for the linear expansion factor alphasbsp{A}{3}(z) is new.

  9. A quantum Mermin-Wagner theorem for quantum rotators on two-dimensional graphs

    NASA Astrophysics Data System (ADS)

    Kelbert, Mark; Suhov, Yurii

    2013-03-01

    This is the first of a series of papers considering symmetry properties of quantum systems over 2D graphs or manifolds, with continuous spins, in the spirit of the Mermin-Wagner theorem [N. D. Mermin and H. Wagner, "Absence of ferromagnetism or antiferromagnetism in one- or two-dimensional isotropic Heisenberg models," Phys. Rev. Lett. 17, 1133-1136 (1966)], 10.1103/PhysRevLett.17.1133. In the model considered here (quantum rotators), the phase space of a single spin is a d-dimensional torus M, and spins (or particles) are attached to sites of a graph (Γ,E) satisfying a special bi-dimensionality property. The kinetic energy part of the Hamiltonian is minus a half of the Laplace operator -Δ/2 on M. We assume that the interaction potential is C2-smooth and invariant under the action of a connected Lie group G (i.e., a Euclidean space {{R}}^{d^' }} or a torus M' of dimension d' ⩽ d) on M preserving the flat Riemannian metric. A part of our approach is to give a definition (and a construction) of a class of infinite-volume Gibbs states for the systems under consideration (the class {G}). This class contains the so-called limit Gibbs states, with or without boundary conditions. We use ideas and techniques originated from papers [R. L. Dobrushin and S. B. Shlosman, "Absence of breakdown of continuous symmetry in two-dimensional models of statistical physics," Commun. Math. Phys. 42, 31-40 (1975), 10.1007/BF01609432; C.-E. Pfister, "On the symmetry of the Gibbs states in two-dimensional lattice systems," Commun. Math. Phys. 79, 181-188 (1981), 10.1007/BF01942060; J. Fröhlich and C. Pfister, "On the absence of spontaneous symmetry breaking and of crystalline ordering in two-dimensional systems," Commun. Math. Phys. 81, 277-298 (1981), 10.1007/BF01208901; B. Simon and A. Sokal, "Rigorous entropy-energy arguments," J. Stat. Phys. 25, 679-694 (1981), 10.1007/BF01022362; D. Ioffe, S. Shlosman and Y. Velenik, "2D models of statistical physics with continuous symmetry: The

  10. PREFACE: Rusnanotech 2010 International Forum on Nanotechnology

    NASA Astrophysics Data System (ADS)

    Kazaryan, Konstantin

    2011-03-01

    Deputy Director, Institute of Semiconductor Physics, Siberian Branch of Russian Academy of Sciences, RussiaProf Vladimir Kvardakov, Corresponding Member of Russian Academy of SciencesExecutive Director, Kurchatov Center of Synchrotron Radiation and Nanotechnology, RussiaProf Edward Son, Corresponding member of Russian Academy of SciencesScientific Deputy Director, Joint Institute for High Temperatures, Russian Academy of Sciences, RussiaProf Andrey GudkovSenior Vice President, Basic Science Chairman, Department of Cell Stress Biology, Roswell Park Cancer Institute, USAProf Robert NemanichChair, Department of Physics, Arizona State University, USAProf Kandlikar SatishProfessor, Rochester Institute of Technology, USAProf Xiang ZhangUC Berkeley, Director of NSF Nano-scale Science and Engineering Center (NSEC), USAProf Andrei ZvyaginProfessor, Macquarie University, AustraliaProf Sergey KalyuzhnyDirector of the Scientific and Technological Expertise Department, RUSNANO, RussiaKonstantin Kazaryan, PhDExpert of the Scientific and Technological Expertise Department, RUSNANO, Russia, Program Committee SecretarySimeon ZhavoronkovHead of Nanotechnology Programs Development Office, Rusnanotech Forum Fund for the Nanotechnology Development, Russia Editors of the proceedings: Section "Nanoelectronics" - Corresponding Member of Russian Academy of Sciences, Professor Anatoly Dvurechenskii (Institute of Semiconductor Physics, RAS).Section "Nanophotonics" - Professor Vasily Klimov (Institute of Physics, RAS).Section "Nanodiagnostics" - Professor P Kashkarov (Russian Scientific Center, Kurchatov Institute).Section "Nanotechnology for power engineering" - Corresponding Member of Russian Academy of Sciences, Professor Eduard Son (Joint Institute for High Temperatures, RAS).Section "Catalysis and chemical industry" - Member of Russian Academy of Sciences, Professor Valentin Parmon (Institute of Catalysis SB RAS).Section "Nanomaterials" - E Obraztsova, PhD (Institute of Physics, RAS), Marat Gallamov Ph

  11. New method to determine initial surface water displacement at tsunami source

    NASA Astrophysics Data System (ADS)

    Lavrentyev, Mikhail; Romanenko, Alexey; Tatarintsev, Pavel

    2013-04-01

    earthquake. However, today it is not yet possible. Ground-based sea radars. This is an effective tool for direct measurement of tsunami wave. At the same time, the wave is measured at a rather narrow area in front of the radar and does not include information about neighboring parts of the wave. Direct measurement of tsunami wave at deep water [2]. Today, this technology is certainly among the most useful and promising. The DART II® system consists of a seafloor bottom pressure recording (BPR) system, capable of detecting tsunamis as small as 1 cm, and a moored surface buoy for real-time communications. We focus our research on improving the later method, direct measurement of tsunami wave at deep water. We suggest the new way to analyze DART data, modifying the methodology originally proposed by V. Titov. Smaller system of unit sources [3] should be considered to approximate all typical shapes of initial disturbance by several suitable basis functions. To successfully implement it, performance of data analysis should be dramatically improved. This could be done by using a signal orthogonalization procedure for considered system of unit sources and calculation of Fourier coefficients of the measured time series with respect to orthogonal basis. The approach suggested was used as a part of computerized workstation for tsunami hazard monitoring [5-6]. National Oceanic and Atmospheric Administration Center for Tsunami Research. URL: http://nctr.pmel.noaa.gov/honshu20110311/ National Data Buoy Center. URL: http://www.ndbc.noaa.gov/dart.shtml National Oceanic and Atmospheric Administration Center for Tsunami Research. URL: http://sift.pmel.noaa.gov/thredds/dodsC/uncompressed/ National Oceanic and Atmospheric Administration Center for Tsunami Research. URL: http://nctr.pmel.noaa.gov/model.html Alexey Romanenko, Mikhail Lavrentiev-jr, Vasily Titov, "Modern Architecture for Tsunami Hazard Mitigation" // Asia Oceania Geosciences Society (AOGS-2012), ISBN 978-981-07-2049-0 Mikhail

  12. EDITORIAL: Focus on Cloaking and Transformation Optics

    NASA Astrophysics Data System (ADS)

    Leonhardt, Ulf; Smith, David R.

    2008-11-01

    coordinate transformations. If the coordinates they conjure up run backwards one gets negative refraction, if they exclude some region of space one makes anything inside invisible [4]. In physics, general relativity has honed the theoretical tools for understanding curved space and curved-coordinate transformations. In transformation optics, general relativity has become a theoretical tool for solving practical engineering problems [4]. What an unorthodox connection! This focus issue represents a snapshot of this rapidly developing research area. It is not restricted to optics or electromagnetism, though. Metamaterials for acoustics also exist and can be applied in ways similar to optical metamaterials. So transformation optics not only attracts an unusual mix of scientists, but also spans a range of applications in optics and beyond. Transformation optics has the potential to transform optics, for example by visualizing invisibility and making materials beyond materials—metamaterials. But before we transgress the boundaries to the hermeneutics of transformation optics [5], let the papers speak for themselves. References [1] Yao J, Liu Z, Liu Y, Wang Y, Sun C, Bartal G, Stacy A M and Zhang X 2008 Science 321 930 [2] Valentine J, Zhang S, Zentgraf T, Ulin-Avila E, Genov D A, Bartal G and Zhang X 2008 Nature 455 376 [3] Schurig D, Mock J J, Justice B J, Cummer S A, Pendry J B, Starr A F and Smith D R 2006 Science 314 977 [4] Leonhardt U and Philbin T G 2006 New J. Phys. 8 247 [5] Sokal A D 1996 Social Text 14(46/47) 217 Focus on Cloaking and Transformation Optics Contents Transformation optics for the full dielectric electromagnetic cloak and metal-dielectric planar hyperlens D P Gaillot, C Croënne, F Zhang and D Lippens Transmutation of singularities in optical instruments Tomáš Tyc and Ulf Leonhardt Electromagnetic cloaking with canonical spiral inclusions K Guven, E Saenz, R Gonzalo, E Ozbay and S Tretyakov Theory and potentials of multi-layered plasmonic covers for

  13. Interglacial-glacial cycles recorded in the deposit sequence at Kruzhyky on the Dniester River (East Carpathian Foreland)

    NASA Astrophysics Data System (ADS)

    Łanczont, Maria; Boguckyj, Aandrij; Mroczek, Przemysław; Zieliński, Paweł; Jacyszyn, Andrij; Pidek, Agnieszka I.; Urban, Danuta; Kulesza, Piotr; Hołub, Beata

    2010-01-01

    of sands with horizontal stratification and silts with horizontal or flaser lamination; single small-scale lithofacies of sands with trough cross-stratification occur in places; single gravel grains are numerous. Two deformation horizons are found: the higher one is characterized by the occurrence of folds and flexure deflections, and the lower one-involution structures and casts of ice wedges/fissures. This complex is probably the result of deposition on the distal part of flat, periodically inundated fluvioglacial fan connected with advancing ice sheet. 4. Ablation complex-sandy or sandy-silty diamicton occurring as isolated inserts, lenses or tongues. Its lower boundary is sharp, erosional and uneven (concave). This complex represents flows of supraglacial tills, which strongly deformed the deposits of the underlying complex 3. 5. Aeolian complex-silty (loess) and sandy-silty (Table 1) deposits with distinct traces of intensive, postsedimentary alterations of pedogenesis of different ages (Tables 1 and 2). It is composed of two soil units separated by thin, primary loess layer: a) older, well-developed paleosol with several pedofeatures very typical of the Sokal (Mazovian) soil; b) younger unit developed as pedocomplex consisting of two mature soils, the upper of which ("modern" neosol) is formed in the top of relict and exhumed paleosol. The described paleosols should be recognized as at least two soils of different ages and of interglacial rank, developed in periglacial loess-like deposits. The Kruzhyky profile is unique in the Dniester River valley. On account of its situation, it supplements the former information about the terrace 5 structure, which has been determined in detail in the Halyč site. And what is most important, it is the only site on the terrace 5 where glacial deposits were found. Lithofacial analysis carried out in the profile enables us to reconstruct the following events reflecting interglacial-glacial cycles: 1. The lowest, gravelly

  14. List of Participants

    NASA Astrophysics Data System (ADS)

    2007-11-01

    Physique Théorique, École Polytechnique, Palaiseau Diego Mansi Università Degli Studi di Milano Matteo Marescotti Università del Piemonte Orientale, Alessandria Alberto Mariotti Università di Milano-Bicocca Raffaele Marotta Istituto Nazionale di Fisica Nucleare, Napoli Alessio Marrani Istituto Nazionale di Fisica Nucleare and LNF, Firenze Luca Martucci Instituto de Física Teórica, Madrid and Katholieke Universiteit Leuven David Mateos University of California, Santa Barbara Andrea Mauri Università di Milano Liuba Mazzanti Università di Milano-Bicocca Patrick Meessen Instituto de Física Teórica, Universidad Autónoma de Madrid Lotta Mether Helsinki Institute of Physics Rene Meyer Max-Planck-Institut für Physik, München Giuseppe Milanesi SISSA, Trieste Cesar Miquel-Espanya Universitat de Valencia and Instituto de Física Corpuscular, Valencia Alexander Monin Institute for Theoretical and Experimental Physics (ITEP), Moscow and Moscow State University (MSU) Samuel Monnier Université de Genève Sergio Montero Instituto de Física Teórica, Madrid Nicola Mori Università di Firenze Alexander Marcel Morisse University of California, Santa Cruz Sebastian Moster Max-Planck-Institut für Physik, München Adele Nasti Queen Mary, University of London Vasilis Niarchos École Polytechnique, Palaiseau Emil Nissimov Institute for Nuclear Research and Nuclear Energy, Sofia Francesco Nitti École Polytechnique, Palaiseau Eoin O'Colgain Imperial College, London Niels Obers Niels Bohr Institute, København Rodrigo Olea Università Degli Studi di Milano Marta Orselli Niels Bohr Institute, København Enrico PajerLudwig-Maximilians-Universität, München Eran PaltiOxford University Georgios PapathanasiouBrown University, Providence, RI Angel ParedesCentre de Physique Théorique, École Polytechnique, Palaiseau Jeong-Hyuck ParkMax-Planck-Institut für Physik, München Sara PasquettiUniversità di Parma Silvia PenatiUniversità di Milano-Bicocca Igor PesandoUniversità di Torino